Document:

2015 Q2 EX 10-91 2016 Supply Agreement

EXHIBIT 10.91

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

2016 SUPPLY AGREEMENT
This 2016 SUPPLY AGREEMENT is made and entered into on this 10th day of February, 2015 (the “Agreement Date”) and shall be effective as of January 1, 2016 (the “Effective Date”), by and among MICRON TECHNOLOGY, INC., a Delaware corporation (“Micron”), MICRON SEMICONDUCTOR ASIA PTE. LTD., a Singapore private limited company and wholly-owned Subsidiary (as defined hereinafter) of Micron (the “Purchaser”), and INOTERA MEMORIES, INC. (Inotera Memories, Inc. [Translation from Chinese]), a company incorporated under the laws of the Republic of China (the “R.O.C.”) (“Inotera”).
RECITALS
A.    Inotera is engaged in the manufacture of DRAM Products (as defined hereinafter) in wafer form.
B.    Micron, the Purchaser and Inotera (each, a “Party” and collectively, the “Parties”) desire Inotera to generally supply Conforming Wafers (as defined hereinafter), Pre-Qual Wafers (as defined hereinafter) and Non-Conforming Wafers (as defined hereinafter) to the Purchaser upon the terms and subject to the conditions set forth in this Agreement.
C.    On the Agreement Date, the Parties have made and entered into the 2015 Supply Agreement, dated the Agreement Date and effective as of the Agreement Date, by and among the Parties (the “2015 Supply Agreement”), to amend and restate the First Amended and Restated Supply Agreement, dated December 19, 2013 and effective as of January 1, 2014, by and among the Parties (the “Existing Supply Agreement”).
D.    The Parties desire to replace the 2015 Supply Agreement, which continues in effect through December 31, 2015, with this Agreement commencing January 1, 2016.
E.    It is the present intention of the Parties that the level of mutual cooperation and support among the Parties in connection with their performance of this Agreement be consistent with the level of mutual cooperation and support among the Parties in connection with their performance of the Existing Supply Agreement.
AGREEMENT
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound do hereby agree as follows:

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ARTICLE 1DEFINITIONS; CERTAIN INTERPRETIVE MATTERS
1.1    Definitions.  In addition to the terms defined elsewhere in this Agreement, capitalized terms used in this Agreement shall have the respective meanings set forth below: 
“Affiliate” means, with respect to any specified Person, any other Person that directly or indirectly, including through one or more intermediaries, Controls, or is Controlled by, or is under common Control with such specified Person; and the term “affiliated” has a meaning correlative to the foregoing.  
“Agreement” means this 2016 Supply Agreement, together with the Schedules attached hereto (but excluding the sample calculations set forth in any attachments to such Schedules, which are provided for illustrative purposes only and shall not constitute terms hereof).
“Agreement Date” shall have the meaning set forth in the preamble to this Agreement.
“Annual Calendar” shall have the meaning set forth in Section 3.2.
“Applicable Law” means any applicable laws, statutes, rules, regulations, ordinances, orders, codes, arbitration awards, judgments, decrees or other legal requirements of any Governmental Entity.
“Boundary Conditions” means, with respect to the Inotera Fab, a requirement that, at any point in time:
(a)    there shall be [***] in use for the manufacture of DRAM Products, provided that at the Inotera Fab, there also may be [***] in use for [***];
(b)    the Inotera Fab shall manufacture for the Purchaser  DRAM Products with [***]; provided, however, that if at any time the Inotera Fab is manufacturing for the Purchaser DRAM Products with [***] (or, if and when the [***] at the Inotera Fab, such [***] as is agreed in writing by the Parties) and the Purchaser requests that the Inotera Fab manufacture for the Purchaser DRAM Products with [***] by the Inotera Fab, the Inotera Fab shall also manufacture for the Purchaser DRAM Products with [***] manufactured by the Inotera Fab [***] to manufacture DRAM Products with [***], including such [***], would be [***] the following for [***] in the [***] the Inotera Fab [***] being manufactured by or for Micron and its Affiliates at such fab [***] for the Inotera Fab, [***] being manufactured at [***] at the Inotera Fab [***] DRAM Products (in wafer form) meeting the applicable specifications that can be manufactured by or for Micron and its Affiliates at [***]; provided further, however, that the foregoing shall be applied only to determine whether the Inotera Fab [***] manufacture DRAM Products with [***] manufactured by the Inotera Fab and only in the circumstance specified above and that the foregoing shall not be applied [***] or otherwise [***] in any circumstance [***] the Purchaser to [***] the Inotera Fab to manufacture for the Purchaser DRAM Products with [***] manufactured by the Inotera Fab; and

DLI-266519827v1
2

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(c)    whenever new DRAM Products of a particular Design ID are introduced by a lead fab into the Inotera Fab (as a receiving fab), Inotera [***] manufacture such DRAM Products for the Purchaser [***] that have been mutually agreed in writing by the Parties prior to the introduction of such DRAM Products;
as such requirement may be altered from time to time by the Purchaser with the consent of Inotera, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that, notwithstanding anything above to the contrary, DRAM Products that are manufactured [***] shall be deemed to be DRAM Products of a [***] for purposes of the [***] described in clause (b) above.
“Business Day” means a day that is not a Saturday, Sunday or other day on which commercial banking institutions in either the R.O.C. or the State of New York are authorized or required by Applicable Law to be closed.
“Business Plan” means, at any particular time, the three (3) year business plan then existing for Inotera, as approved by the board of directors of Inotera.
“Closing Date” shall mean January 17, 2013.
“Committed Purchaser Manufacturing Capacity” means:
(a)    at any time during the Term, 100% of the Manufacturing Capacity for each Process Node installed at the Inotera Fab; and
(b)    at any time during the Purchaser Wind-Down Period, the portion of the Manufacturing Capacity for each Process Node installed at the Inotera Fab as determined in accordance with Sections 11.1(e) and 11.1(f).
“Conforming Wafer” means a wafer containing DRAM Products produced by Inotera for delivery to the Purchaser under this Agreement following the qualification of such DRAM Products that (a) meets the applicable Specifications for a Conforming Wafer containing such DRAM Products immediately after Probe Testing and (b) has a minimum Die Yield equal to [***]% (or, if the minimum die yield required for conforming wafers containing such DRAM Products in other fabs in the Micron Fab Network is different than [***]%, then such different percentage, which shall be set forth in a written notice to Inotera from Micron or the Purchaser).
“Control” means the power or authority, whether exercised or not, to direct the business, management and policies of a Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, which power or authority shall conclusively be presumed to exist upon possession of beneficial ownership or power to direct the vote of more than fifty percent (50%) of the votes entitled to be cast at a meeting of the members, shareholders or other equity holders of such Person or power to control the composition of a majority of the board of directors or like governing body of such Person; and the term “Controlled” has a meaning correlative to the foregoing. 

DLI-266519827v1
3

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Cycle-Time” means the time required to process a wafer through a portion of the manufacturing process or through the manufacturing process as a whole, including Probe Testing.
“Delivery Month” means, with respect to any particular wafer delivered to the Purchaser pursuant to this Agreement, the Fiscal Month in which it is delivered to the Purchaser.
“Demand Forecast” shall have the meaning set forth in Section 3.4.
“Design ID” means a part number that is assigned to a unique DRAM Design of a particular DRAM Product, which may include a number or letter designating a specific device revision. 
“Die Yield” means the quotient, expressed as a percentage, of (a) the number of DRAM Products in die form that are manufactured on a wafer and that meet the applicable Specifications for such DRAM Products immediately after Probe Testing, divided by (b) the maximum number of such die that could be manufactured on such wafer to meet the applicable Specifications for such wafer using the applicable Process Node.
“DRAM” means a dynamic random access memory cell that functions by using a capacitor arrayed predominantly above the semiconductor substrate.  
“DRAM Design” means all of the design elements, components, specifications and information required to manufacture the subject DRAM Product.
“DRAM Product” means any memory comprising DRAM, whether in die or wafer form.
“Effective Date” shall have the meaning set forth in the preamble to this Agreement.
“Environmental Laws” means any and all laws, statutes, rules, regulations, ordinances, orders, codes or binding determinations of any Governmental Entity pertaining to the environment in any and all jurisdictions in which the Inotera Fab is located, including laws pertaining to the handling of wastes or the use, maintenance and closure of pits and impoundments, and other environmental conservation or protection laws. 
“Excursion” means a performance deviation during the production process that is outside normal behavior, as defined by historical performance or as established by the Purchaser and Inotera in writing in the applicable Specifications, which may impact performance, Quality and Reliability or the Purchaser’s customer delivery commitments for DRAM Product from Conforming Wafers. 

DLI-266519827v1
4

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Existing Supply Agreement” shall have the meaning set forth in Recital C to this Agreement.
“Final Conforming Wafer Price” shall have the meaning set forth in Section 5.1(c).
“Final Invoice” shall have the meaning set forth in Section 4.9(b).
“Fiscal Month” means any of the twelve financial accounting months within the Fiscal Year.
“Fiscal Quarter” means any of the four financial accounting quarters within the Fiscal Year.
“Fiscal Year” means the fiscal year of Inotera for financial accounting purposes.
“Force Majeure Event” means the occurrence of an event or circumstance beyond the reasonable control of the Party and includes:  (a) explosions, fires, flood, earthquakes, catastrophic weather conditions, or other elements of nature or acts of God; (b) acts of war (declared or undeclared), acts of terrorism, insurrection, riots, civil disorders, rebellion or sabotage; (c) acts of Governmental Entities; (d) labor disputes, lockouts, strikes or other industrial action, whether direct or indirect and whether lawful or unlawful; (e) failures or fluctuations in electrical power or telecommunications service or equipment; and (f) delays caused by nonperformance of Inotera, in the case of Micron or the Purchaser, or Micron or the Purchaser, in the case of Inotera, or nonperformance by a Third Party  (except for delays caused by such Party’s subcontractors or agents). 
“GAAP” means generally accepted accounting principles.
“Governmental Entity” means any governmental authority or entity, including any agency, board, bureau, commission, court, municipality, department, subdivision or instrumentality thereof, or any arbitrator or arbitration panel. 
“Hazardous Substances” means any asbestos, any flammable, explosive, radioactive, hazardous, toxic, contaminating, polluting matter, waste or substance, including any material defined or designated as a hazardous or toxic waste, material or substance, or other similar term, under any Environmental Laws in effect or that may be promulgated in the future.
“HMC Conforming Wafer” means Conforming Wafers for HMC DRAM Products.
“HMC DRAM” means a hybrid memory cube dynamic random access memory cell that is intended to be coupled with a controller or logic chip.
“HMC DRAM Product” means any memory comprising HMC DRAM, whether in die or wafer form.

DLI-266519827v1
5

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“HMC Pre-Qual Wafers” means Pre-Qual Wafers for HMC DRAM Products.
“HMC Wafer” means a wafer containing HMC DRAM Products.
“Indemnified Losses” mean all direct, out-of-pocket liabilities, damages, losses, costs and expenses (including reasonable attorneys’ and consultants’ fees and expenses).
“Indemnified Party” shall have the meaning set forth in Section 9.2(a).
“Indemnifying Party” shall have the meaning set forth in Section 9.2(a).
“Inotera” shall have the meaning set forth in the preamble to this Agreement.
“Inotera Fab” shall have the meaning set forth in Section 1.2(c).
“Inotera Financial Report” shall have the meaning set forth in Section 3.8.
“Joint Venture Agreement” means that certain Joint Venture Agreement between MNL, Numonyx B.V., MTAP and NTC, dated as of the Closing Date, as amended, relating to Inotera.
“Line Yield” means, for any given period of time, the quotient, expressed as a percentage, of (a) the number of Conforming Wafers and Pre-Qual Wafers produced during such period of time, divided by (b) the number of all wafers started during such period of time. 
“Long Range Forecast” shall have the meaning set forth in Section 3.12.
“Manufacturing Capacity” means, for each Process Node at the Inotera Fab for any particular period of time, the maximum number of Conforming Wafers that can be manufactured through Probe Testing and delivered to the Purchaser utilizing such Process Node at the Inotera Fab during such period of time, assuming Inotera only manufactured Conforming Wafers during such period of time.
“Manufacturing Plan” shall have the meaning set forth in Section 3.1.
“Micron” shall have the meaning set forth in the preamble to this Agreement.
“Micron Fab Network” means the fabs manufacturing DRAM Products for Micron and its Affiliates, including the Inotera Fab.  
“Micron/Inotera Confidentiality Agreement” means that certain Mutual Nondisclosure Agreement between Micron and Inotera, dated as of the Closing Date, as amended.
“MNL” means Micron Semiconductor B.V., a private limited liability company organized under the laws of the Netherlands.

DLI-266519827v1
6

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Monthly Planning Statement” shall have the meaning set forth in Section 3.3.
“Monthly Financial Review” shall have the meaning set forth in Section 3.11(b).
“MTAP” means Micron Technology Asia Pacific, Inc., an Idaho corporation.
“Non-Conforming Wafer” means a wafer containing DRAM Products produced by Inotera for delivery to the Purchaser under this Agreement following the qualification of such DRAM Products that (a) fails to meet the applicable Specifications for a Conforming Wafer containing such DRAM Products immediately after Probe Testing or (b) has a minimum Die Yield below that required for a Conforming Wafer of such DRAM Products.
“Non-HMC Conforming Wafer” means Conforming Wafers for Non-HMC DRAM Products.
“Non-HMC DRAM Product” means any memory comprising DRAM and excluding HMC DRAM, whether in die or wafer form.
“Non-HMC Pre-Qual Wafers” means Pre-Qual Wafers for Non-HMC DRAM Products.
“NTC” means Nanya Technology Corporation (Nanya Technology Corporation [Translation from Chinese]), a company incorporated under the laws of the R.O.C.
“Numonyx B.V.” means Numonyx Holdings B.V., a private limited liability company organized under the laws of the Netherlands.
“Operational Report” shall have the meaning set forth in Section 3.9.
“Party” and “Parties” shall have the meanings set forth in Recital B to this Agreement.
“Performance Criteria” means the factors of [***].
“Permitted Disclosures” shall have the meaning set forth in Section 3.13.
“Person” means any natural person, corporation, joint stock company, limited liability company, association, partnership, firm, joint venture, organization, business, trust, estate or any other entity or organization of any kind or character.
“Preliminary Price” means, for a particular Delivery Month, (a) with respect to Non-HMC Conforming Wafers, Inotera’s estimate, as of the time Inotera delivers the Preliminary Price Notice with respect to such Delivery Month, of the Price that Inotera will charge pursuant to Section 5.1(a) for such Non-HMC Conforming Wafers, as reasonably determined by Inotera, with such estimate being based on the Price of such Non-HMC Conforming Wafers [***] or, if there is no [***], [***] consistent with the historical practices of the Parties, (b) with respect to Non-HMC Pre-Qual Wafers, Inotera’s estimate, as of the time Inotera delivers the Preliminary Price Notice with respect to such 

DLI-266519827v1
7

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

Delivery Month, of the Price that Inotera will charge pursuant to Section 5.2(a) for such Non-HMC Pre‐Qual Wafers, (c) with respect to HMC Conforming Wafers and HMC Pre-Qual Wafers, Inotera’s estimate of [***] to be negotiated in good faith by the Parties pursuant to Section 5.1(b) and 5.2(b) prior to Inotera loading any HMC Wafers; and (d) with respect to Non-Conforming Wafers, an amount [***] per Non‐Conforming Wafer, as mutually agreed in writing by the Parties.
“Preliminary Price Notices” shall have the meaning set forth in Section 4.4(a).
“Pre-Qual Engineering Wafers” means Pre-Qual Wafers that are not Pre-Qual Production Wafers.
“Pre-Qual Production Wafers” means, with respect to a particular DRAM Product, the Pre-Qual Wafers having a qualification plan and delivered by Inotera [***] of a particular Design ID provided that [***] has [***] as of the beginning of the respective Delivery Month.
“Pre-Qual Wafers” means, with respect to a particular DRAM Product, wafers of such DRAM Product requested by the Purchaser for delivery to the Purchaser in lieu of Conforming Wafers in any Purchase Order placed, or any change order to a Purchase Order issued, as contemplated by Section 4.3, that are manufactured to the full extent of the applicable process flow but prior to the qualification of such DRAM Product at the Inotera Fab.
“Price” shall have the meaning set forth in Article 5.
“Price True-Up Amount” means, for a particular Delivery Month, an amount, which may be positive or negative, equal to the sum of (i) the sum of (A) the aggregate Final Conforming Wafer Price of the Non-HMC Conforming Wafers and HMC Conforming Wafers delivered during such Delivery Month to the Purchaser calculated in accordance with Section 5.1(c), plus (B) the aggregate Price of the Non-HMC Pre-Qual Wafers and HMC Pre-Qual Wafers delivered during such Delivery Month to the purchaser calculated in accordance with Section 5.2, minus (ii) the aggregate balance owing to Inotera shown on all Pro Forma Invoices accompanying the deliveries of Non-HMC Conforming Wafers, HMC Conforming Wafers, Non-HMC Pre-Qual Wafers, HMC Pre-Qual Wafers and Non-Conforming Wafers during such Delivery Month to the Purchaser.
“Probe Testing” means testing, using a wafer test program as set forth in the applicable Specifications for such wafer, of a wafer that has completed all processing steps deemed necessary to complete the creation of the desired integrated circuits in the die on such wafer, the purpose of which test is to determine how many and which of the die meet the applicable criteria for such die set forth in the Specifications for such die.
“Probe Yield” means, with respect to any period of time, the quotient, expressed as a percentage, of (a) the number of DRAM Products in die form meeting the applicable Specifications for such DRAM Products during such period of time, divided by (b) the maximum number of die on Conforming Wafers probed during such period of time.

DLI-266519827v1
8

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Process Node” means a collection of process technology and equipment that enables the production of DRAM Products in wafer form for a particular minimum repeatable half pitch of a device (minimum physical feature size or line width) and often designated by the size of such pitch (e.g., the 42nm Process Node or the 30nm Process Node, etc.).  For the avoidance of doubt, the Parties acknowledge and agree that the [***] Process Node utilized at the Inotera Fab is not the same Process Node as the [***] Process Node utilized by [***].
“Process Node Allocation Notice” shall have the meaning set forth in Section 11.1(f).
“Pro Forma Invoice” shall have the meaning set forth in Section 4.9(a).
“Purchase Order” shall have the meaning set forth in Section 4.4(b).
“Purchaser” shall have the meaning set forth in the preamble to this Agreement.
“Purchaser Indemnified Party” means the Purchaser or any of its Affiliates, including Micron.
“Purchaser Pricing Report” shall have the meaning set forth in Section 3.10.
“Purchaser Wind-Down Period” shall have the meaning set forth in Section 11.1(d).
“Quality and Reliability” means the quality and reliability standards for Conforming Wafers as set forth in Schedule 1.1 and the applicable Specifications for such Conforming Wafers or the Manufacturing Plan in effect from time to time.
“Quarterly Business Review” has the meaning set forth on Section 3.11(a).
“Recoverable Taxes” shall have the meaning set forth in Section 4.8(a).
“Response to Forecast” shall have the meaning set forth in Section 3.5.
“Restriction Period” means, with respect to any Segregated Employee, the period of time beginning on the date such Person becomes a Segregated Employee and ending on the date that is [***] months after the date such Person is no longer a Segregated Employee.
“R.O.C.” shall have the meaning set forth in the preamble to this Agreement.
“[***] Payment Amount” shall have the meaning set forth in Section 3.10.
“Segregated Employees” means (a) the accounting employees of Inotera that are responsible for performing, reviewing and approving the calculation of the Price for any DRAM Product sold to the Purchaser under this Agreement, and (b) the president of Inotera and the senior officer responsible for financial management of Inotera, provided that no [***], if any, shall be permitted to be a Segregated Employee.

DLI-266519827v1
9

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Shared Design ID Wafers” means all wafers with the same Design ID that are produced for both the Purchaser and other Persons.
“Ship Lot Line Yield” means, with respect to any lot of wafers, the quotient, expressed as a percentage, of (a) the number of Conforming Wafers manufactured from such lot, divided by (b) the number of Wafer Starts from such lot.
“Specifications” means those specifications used to describe, characterize, and define the quality and performance of a Conforming Wafer or a DRAM Product in die form, as applicable, in each case, as such specifications may be set forth on Schedule 1.1 or otherwise determined from time to time by the Purchaser and delivered in writing to Inotera ; provided, however, that (a) with respect to specifications not in effect on the Effective Date, (i) promptly upon receipt by Inotera from the Purchaser of such specifications, Inotera shall evaluate such specifications and, without undue delay, the Purchaser and Inotera shall mutually agree upon the effective date for such specifications (which date shall in no event be more than [***] days following Inotera’s receipt of such specifications from the Purchaser, unless a later date is agreed upon by the Purchaser and Inotera) and (ii) upon reaching such agreement, Inotera shall confirm to the Purchaser in writing the agreed effective date for such specifications and (b) specifications delivered by the Purchaser to Inotera for Conforming Wafers containing a particular DRAM Product or a DRAM Product in die form shall [***] specifications for wafers containing such particular DRAM Product or such DRAM Product in die form, as applicable (if any), [***].
“Subsidiary” means, with respect to any specified Person, any other Person that directly or indirectly, including through one or more intermediaries, is Controlled by such specified Person. 
“Taiwan GAAP” means GAAP used in the R.O.C., as in effect from time to time, consistently applied for all periods at issue.
“Term” shall have the meaning set forth in Section 11.1(a).
“Third Party” means any Person, other than Micron, Inotera or any of their respective Subsidiaries.
“Third Party Claim” means any claim, demand, lawsuit, complaint, cross-complaint or counter-complaint, arbitration, opposition, cancellation proceeding or other legal or arbitral proceeding of any nature brought in any court, tribunal or judicial forum anywhere in the world, regardless of the manner in which such proceeding is captioned or styled brought by any Third Party.

DLI-266519827v1
10

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“2015 Supply Agreement” shall have the meaning set forth in Recital C to this Agreement.
“Wafer Start” means the initiation of manufacturing services with respect to a wafer.
“WIP” means work in process at the Inotera Fab, including all wafers in wafer fabrication and sort and all completed Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers not yet delivered to the Purchaser or other Persons.
“WIP Data” means in-line inventory data, including wafer numbers, lot numbers, unit volumes, wafer volumes, Cycle-Times, Die Yield, Line Yield, Probe Yield and Ship Lot Line Yield.
1.2    Certain Interpretive Matters.
(a)    Unless the context requires otherwise, (i) all references to Sections, Articles, Exhibits, Appendices or Schedules are to Sections, Articles, Exhibits, Appendices or Schedules of or to this Agreement, (ii) except as otherwise provided in Schedule 5.1(a) or Schedule 5.2(a), each accounting term not otherwise defined in this Agreement (A) with respect to Micron or the Purchaser, has the meaning commonly applied to it in accordance with GAAP used in the United States, as in effect from time to time, consistently applied for all periods at issue, and (B) with respect to Inotera, has the meaning commonly applied to it in accordance with Taiwan GAAP, (iii) words in the singular include the plural and vice versa, (iv) the term “including” means “including without limitation,” and (v) the terms “herein,” “hereof,” “hereunder” and words of similar import shall mean references to this Agreement as a whole and not to any individual section or portion hereof.  All references to “$” or dollar amounts will be to lawful currency of the United States of America.  All references to “day” or “days” mean calendar days, and all references to “quarter(ly),” “month(ly)” or “year(ly)” mean Fiscal Quarter, Fiscal Month or Fiscal Year, respectively, unless the context requires otherwise.
(b)    No provision of this Agreement will be interpreted in favor of, or against, any Party by reason of the extent to which (i) such Party or its counsel participated in the drafting thereof, or (ii) such provision is inconsistent with any prior draft of this Agreement or such provision.
(c)    For purposes of this Agreement, the “Inotera Fab” shall mean collectively the existing fabs of Inotera commonly referred to as “Fab 1,” “Fab 2” and “Fab 1A” located at Hwa Ya Technology Park, Taoyuan, Taiwan.
(d)    Notwithstanding anything herein to the contrary, the example calculations set forth in any attachments to the Schedules hereto shall not constitute terms of this Agreement and are provided for illustrative purposes only.  In the event of any conflict between such example calculations and the terms of this Agreement, the terms of this Agreement shall govern and the Parties shall modify such example calculations to be consistent therewith.

DLI-266519827v1
11

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ARTICLE 2
OBLIGATIONS OF THE PARTIES; 
PROCESSES AND CONTROLS
2.1    General Obligations.
(a)    Inotera shall provide, develop and operate the Inotera Fab according to the Business Plan in effect from time to time and the obligations set forth herein (including the planning process set forth in Article 3).
(b)    Inotera shall:
(i)    manufacture Conforming Wafers for the Purchaser in accordance with (A) the applicable Boundary Conditions, (B) the applicable Specifications, (C) the Responses to Forecast developed in response to the Demand Forecasts provided by the Purchaser to Inotera in accordance with Article 3;
(ii)    supply Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers to the Purchaser in accordance with the purchasing process set forth in Article 4; and
(iii)    operate the Inotera Fab so that DRAM Product output from the Inotera Fab does not differ materially from that of any other fab in the Micron Fab Network as to the Specifications and Performance Criteria. 
(c)    The Purchaser shall purchase Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers from Inotera in accordance with the terms and conditions set forth herein.
For the avoidance of doubt, in no event shall Inotera be obligated to load any HMC Wafers unless and until the Parties have first negotiated and agreed as to how to calculate the Price of HMC Conforming Wafers as contemplated by Section 5.1(b) and the Price of HMC Pre-Qual Wafers as contemplated by Section 5.2(b).
2.2    Control; Processes.  The Purchaser and Inotera shall review Inotera’s control and process mechanisms, including such mechanisms that are utilized to ensure that all parameters of the Specifications and Performance Criteria are met or exceeded in Inotera’s manufacture of Conforming Wafers.  The Purchaser and Inotera agree to work together in good faith to define mutually agreeable control and process mechanisms, including the following:  (a) e-test (also known as parametric test capability); (b) qualification methodology plan; (c) product qualification support; (d) Probe Testing capability; (e) change control process; and (f) failure analysis capability and methodology.  Without limiting the generality of the forgoing, the Purchaser and Inotera agree to the control and process mechanisms set forth in Schedule 1.1.

DLI-266519827v1
12

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

2.3    Production Masks.  
(a)    Inotera shall purchase masks required to manufacture [***] for DRAM Products manufactured by Inotera under this Agreement from [***], and Inotera may purchase masks required to manufacture [***] for DRAM Products manufactured by Inotera under this Agreement from [***] (other than [***]) approved in writing by Micron; provided, however, that, with respect to Inotera’s purchase of any [***], such limitations shall not apply if [***] by [***].  Furthermore, [***] shall meet [***] at [***] for [***].  If Inotera elects to purchase masks from [***], (i) subject to [***] (such [***] to be determined in [***] sole discretion), [***] will provide to [***] the [***] determines, in its sole discretion, are necessary to [***] (which [***] will not be provided under this Agreement but will instead be subject to a separate statement of work to be entered into by [***] and [***] prior to the provision of such [***] by [***]), and (ii) [***] will pay to [***] associated with such [***] on the terms specified in such statement of work (which amounts shall constitute [***]).  Notwithstanding anything in this Section 2.3(a) to the contrary, [***] shall be used for the [***] and any [***] of each [***] for a DRAM Product [***].  Inotera shall have possession, but not ownership of any underlying copyrights, mask works or other intellectual property, of any physical production masks which Inotera obtains in accordance with this Section 2.3(a).
(b)    Inotera shall promptly revise any mask set that is qualified for the manufacture of DRAM Products by Inotera for delivery to the Purchaser under this Agreement as requested [***] by the Purchaser or Micron from time to time.
2.4    Designation of WIP.
(a)    WIP Associated With Shared Design ID Wafers.  Inotera shall ensure that WIP at the Inotera Fab associated with Shared Design ID Wafers is designated for the Purchaser and any other Persons for which it is produced from Wafer Start, and the Shared Design ID Wafers shall be allocated to the Purchaser and such other Persons immediately prior to Probe Testing by Design ID pro rata in accordance with the relative number of Wafer Starts of such Shared Design ID Wafers for each of the Purchaser and such other Persons during the Fiscal Month in which such Shared Design ID Wafers were started. 
(b)    Other WIP.  Inotera shall ensure that WIP at the Inotera Fab associated with wafers (other than the Shared Design ID Wafers contemplated by Section 2.4(a)) to be produced for the Purchaser or any other Person is designated for the Purchaser or such other Person, as applicable, from Wafer Start.
2.5    Subcontractors.  Inotera may utilize [***] as a subcontractor, subject to (a) the prior written approval of the Purchaser, which approval shall not be unreasonably withheld or delayed, and (b) compliance with the guidelines developed to manage the quality of such utilization in effect on the Effective Date (with such changes thereto as may from time to time be agreed in writing by the Parties).  Inotera shall ensure that all contracts with [***] (a) shall provide Inotera with the same 

DLI-266519827v1
13

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

level of access and controls as Inotera provides to the Purchaser in this Agreement and (b) contain customary nondisclosure obligations in a form reasonably acceptable to the Purchaser.
2.6    [***] Notification.  In addition to the Operational Report and the Quarterly Business Review, Inotera shall promptly notify the Purchaser of [***] affecting [***].
2.7    Traceability; Data Retention.  The Purchaser and Inotera shall review Inotera’s (a) [***] and producing the WIP Data and (b) data retention policy in regards to the WIP Data.  Inotera agrees to maintain the WIP Data for a minimum of [***] (or such other period as may be agreed in writing by the Parties).  
2.8    Access to WIP Data.  Inotera shall provide the Purchaser with full access to its WIP Data (including with respect to Shared Design ID Wafers) no less frequently than [***] under normal circumstances, which data shall be no older than [***] old when accessed.
2.9    Additional Customer Requirements.  The Purchaser shall inform Inotera in writing of any supplier requirements of any customer of the Purchaser relating to the Inotera Fab.  The Purchaser and Inotera shall work together in good faith to satisfy such requirements.
ARTICLE 3
PLANNING AND FORECASTING; 
PERFORMANCE REVIEWS AND REPORTS
3.1    Annual Manufacturing Plan.  At least [***] days (or such other number of days as may be agreed in writing by the Parties) prior to the end of each Fiscal Year, Inotera shall prepare, under the direction of the president of Inotera, an annual manufacturing plan (the “Manufacturing Plan”) for the next [***] (or such other period or periods as may be agreed in writing by the Parties) and shall submit the Manufacturing Plan to the Purchaser for its review and comment.  The Manufacturing Plan shall reflect the planning process contained in this Article 3.  The Manufacturing Plan shall address various manufacturing issues, including the DRAM Products to be manufactured, a loading plan (by Design ID and Process Node for the DRAM Products to be produced, including, if applicable, a breakout of the DRAM Products, by Design ID and Process Node, to be produced for any Persons other than the Purchaser) and weekly loading and output (including, if applicable, a breakout, by Design ID and Process Node, the wafers designated for any Persons other than the Purchaser).  The Manufacturing Plan covering [***] shall be agreed by the Parties prior to the Effective Date.
3.2    Annual Calendar.   Prior to the beginning of each Fiscal Year, the Parties shall establish a planning calendar for such Fiscal Year (each, an “Annual Calendar”) that sets forth key planning and finance dates during such Fiscal Year, which may include the dates on which the Parties will (a) deliver the Monthly Planning Statements (or the components thereof), the Demand Forecasts, the Responses to Forecast, the Operational Reports, the Long Range Forecast, the Preliminary Price Notices, the Purchase Orders and any other information that may be agreed in writing by the Parties, and (b) hold the Quarterly Business Reviews and Monthly Financial Reviews 

DLI-266519827v1
14

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

described in Section 3.11, provided that such dates shall be consistent with this Article 3 and Article 4, as applicable, and shall generally be consistent with the Purchaser’s internal planning calendar for such Fiscal Year.  In addition, the Annual Calendar may reflect the dates during such Fiscal Year on which the Parties will be required by this Agreement to deliver Purchaser Pricing Reports, Inotera Financial Reports and Final Invoices.  The Parties may alter the dates described in an Annual Calendar at any time, provided that such altered dates are consistent with this Article 3 and Article 4, as applicable, and are agreed in writing by the Parties.  The Parties will agree to the Annual Calendar for 2016 prior to the Effective Date.
3.3    Monthly Planning Statement.  Each Fiscal Month, Inotera shall deliver to the Purchaser one or more statements (collectively for each Fiscal Month, a “Monthly Planning Statement”) setting forth (a) for each Process Node, the anticipated Committed Purchaser Manufacturing Capacity for each of the next [***] Fiscal Months (or such other period as may be agreed in writing by the Parties) taking into account, among other things, [***] that were included in the Response to Forecast delivered in the prior Fiscal Month, (b) for each Design ID, the [***] as the Purchaser and Inotera may agree in writing for such Design ID for each of the next [***] Fiscal Months and (c) the Boundary Conditions applicable to the next [***] Fiscal Months.
3.4    Demand Forecast.  Following receipt of a Monthly Planning Statement as contemplated by Section 3.3, the Purchaser shall deliver to Inotera a written non-binding forecast of the Purchaser’s demand (each, a “Demand Forecast”) for the [***] Fiscal Months (or such other period as may be agreed in writing by the Parties) covered by such Monthly Planning Statement.  Each Demand Forecast (a) shall include the total number of Conforming Wafers (broken out by Design ID and Process Node) and Pre-Qual Wafers (broken out by Design ID and Process Node) requested by the Purchaser for the period covered by such Demand Forecast (broken out weekly) and (b) shall be consistent with the Committed Purchaser Manufacturing Capacity and Boundary Conditions set forth in the Monthly Planning Statement to which it relates.
3.5    Response to Forecast; Resolution of Conflicts.  Following receipt of a Demand Forecast as contemplated by Section 3.4, Inotera shall deliver to the Purchaser a written response that, so long as such Demand Forecast delivered by the Purchaser is consistent with the Committed Purchaser Manufacturing Capacity and Boundary Conditions set forth in the Monthly Planning Statement to which it relates, indicates Inotera commits to supply Conforming Wafers and Pre-Qual Wafers based on such Demand Forecast (each, a “Response to Forecast”).  In preparing any Response to Forecast at any time the Committed Purchaser Manufacturing Capacity is less than 100% of the Manufacturing Capacity of Inotera at the Inotera Fab, if there is a conflict with respect to the manufacture of wafers for the Purchaser pursuant to this Agreement and the manufacture of wafers or other products for any other Person, such conflict shall be resolved [***] and the manufacture of wafers for the [***].
3.6    Changes to Demand Forecast.  The Purchaser may deliver to Inotera an adjusted Demand Forecast for any purpose, including to reduce the number of Conforming Wafers and Pre-Qual Wafers to be delivered to the Purchaser, to increase the number of Conforming Wafers and Pre-Qual Wafers to be delivered to the Purchaser (if less than all of the Committed Purchaser 

DLI-266519827v1
15

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

Manufacturing Capacity was previously included in the Demand Forecast) and to change the Design ID mix of Conforming Wafers and Pre-Qual Wafers to be manufactured utilizing a particular Process Node, at any time until [***] prior to the scheduled loading of the wafers affected by adjustments reflected in the adjusted Demand Forecast.  In such event, Inotera shall deliver to the Purchaser a revised Response to Forecast that, so long as such adjustments are consistent with the Committed Purchaser Manufacturing Capacity and the Boundary Conditions set forth in the most recently delivered Monthly Planning Statement, indicates Inotera commits to supply Conforming Wafers and Pre-Qual Wafers based on such adjustments.  
3.7    [***] Statements. At least [***], Inotera shall deliver to the Purchaser a statement setting forth the number of Conforming Wafers and Pre-Qual Wafers (in each case, by Design ID) that are anticipated to be delivered to the Purchaser during each of the next [***].  In addition, at least [***], Inotera shall deliver to the Purchaser a statement setting forth:
(a)    by Design ID, the number of Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers that were delivered to the Purchaser in the immediately preceding [***];
(b)    by Design ID, the Die Yield, Line Yield and Cycle-Time in the immediately preceding [***]; and 
(c)    such other Performance Criteria as the Purchaser and Inotera may agree in writing. 
3.8    Inotera Financial Report.  Within [***] days after the end of each Delivery Month in the case of [***] and within [***] Business Days after the end of each Delivery Month in the case of [***] (or such other number of days as may be agreed in writing by the Parties), Inotera shall deliver to the Purchaser a report (each, a “Inotera Financial Report”) which shall include:
(a)    a detailed calculation, by Design ID, of Final Conforming Wafer Price for the Delivery Month just ended;
(b)    a detailed calculation, by Process Node, of JVC Per Design ID, Conforming Wafers JVC Per Design ID and Conforming Wafers JVC Per Wafer Per Node (as each such term is defined in Schedule 5.1(a)) for the Delivery Month just ended;
(c)    if Non-HMC Pre-Qual Wafers were delivered in the Delivery Month just ended, a detailed calculation, by Design ID, of the Price of such Non-HMC Pre-Qual Wafers; 
(d)    if HMC Conforming Wafers and/or HMC Pre-Qual Wafers were delivered in the Delivery Month just ended, a detailed calculation, by Design ID, of the “cost” (as determined in accordance with Section 5.1(b) and/or Section 5.2 (b), as applicable) of such HMC Conforming Wafers and/or HMC Pre-Qual Wafers; and

DLI-266519827v1
16

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(e)    other financial information regarding Inotera for the Delivery Month just ended, consistent with the financial information regarding Inotera that has been historically provided to Micron by Inotera.
The Purchaser will not use or disclose Inotera Financial Reports, or the contents thereof, received by the Purchaser in contravention of any Applicable Law.
3.9    Operational Report.  Each Fiscal Quarter, Inotera shall deliver to the Purchaser a report with respect to the Fiscal Quarter just ended (the “Operational Report”), which shall include:
(a)    a comparison of [***] relative to the [***] delivered in the [***] immediately prior to the [***], together with a comparison of [***] for the next [***] relative to the [***];
(b)    a summary of [***], a summary of [***], including [***] and other indicators that may evidence or impact the [***], and a description of any [***];
(c)    a description of [***] or other [***], including any [***] or other indicator, summarized pursuant to Section 3.9(b); and
(d)    a description of [***] (and [***], if known) that are not reflected in [***] which may [***].
3.10    Purchaser Pricing Report. Each Fiscal Month, as soon as practicable, but no later than [***] days (or such other number of days as may be agreed in writing by the Parties) after the end of the Fiscal Month just ended, the Purchaser shall deliver to Inotera a report (each, a “Purchaser Pricing Report”), which shall include (a) the detailed calculation of the Price of Non-HMC Conforming Wafers, Non-HMC Pre-Qual Wafers, HMC Conforming Wafers and HMC Pre-Qual Wafers delivered in the Fiscal Month just ended and (b) the detailed calculation of the [***] Payment Amount for the Fiscal Month just ended.  The “[***] Payment Amount” for any Fiscal Month shall be calculated in accordance with Schedule 3.10.  Inotera will not use or disclose the Purchaser Pricing Reports, or the contents thereof, received by Inotera in contravention of any Applicable Law.
3.11    Periodic Performance Reviews.
(a)    Inotera shall hold quarterly meetings (each, a “Quarterly Business Review”) with the Purchaser, the primary purposes of which shall be to review and discuss the most recent Operational Report and the Performance Criteria and to mutually agree on operational adjustments if necessary.

DLI-266519827v1
17

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(b)    The Purchaser and Inotera shall hold monthly meetings (each, a “Monthly Financial Review”) to review and discuss (i) at the election of the Purchaser, the Inotera Financial Reports received by the Purchaser since the last such meeting, and (ii) at the election of Inotera, the Purchaser Pricing Reports delivered by the Purchaser since the last such meeting.
3.12    Long Range Forecast.    Each Fiscal Year, the Purchaser will provide Inotera, for its review and comment, with a written non-binding forecast (each, a “Long Range Forecast”) of the Purchaser’s demand for Conforming Wafers and Pre-Qual Wafers for the next [***] or, if the Purchaser Wind-Down Period has commenced, for the remaining duration of the Purchaser Wind-Down Period.
3.13    Restrictions on Access to Pricing Information; Nonsolicitation of Segregated Employees.  
(a)    Inotera shall prevent any Person that is not a Segregated Employee from obtaining access to the pricing information (including the Purchaser Pricing Reports and the Inotera Financial Reports), or the data from which pricing information is derived from, delivered to, or created by, Inotera under this Agreement, except (i) as the Parties may otherwise agree in writing, (ii) as may be required by legal process under Applicable Law, and (iii) that Inotera may provide (A) the Purchaser with Inotera Financial Reports, Preliminary Price Notices, Pro Forma Invoices, Final Invoices and the data from which such Inotera Financial Reports, Preliminary Price Notices, Pro Forma Invoices or Final Invoices are derived, (B) any independent Third Party auditor acting as contemplated by Section 6.4 with such information as such auditor may request that is reasonably relevant to the applicable inspection and audit, and (C) Inotera’s independent outside auditors with such information as such auditor may reasonably request in connection with its audit of Inotera’s financial statements and other statutory audit requirements (the items in clauses (i), (ii) and (iii) being referred to as the “Permitted Disclosures”).  Without limiting the generality of the foregoing, Inotera shall (x) develop, maintain, implement and enforce policies that (A) prohibit all Segregated Employees from disclosing, or allowing disclosure of, pricing information (including the Purchaser Pricing Reports and the Inotera Financial Reports) to Persons that are not Segregated Employees, other than the Permitted Disclosures and (B) require all Segregated Employees to store all physical files related to pricing (including the Purchaser Pricing Reports and the Inotera Financial Reports) in secure locations that are not accessible by non-Segregated Employees, (y) segregate the office space of the Segregated Employees from other employees of Inotera, and (z) maintain all electronic files containing pricing information (including the Purchaser Pricing Reports and the Inotera Financial Reports) in confidential password protected files.  The Purchaser shall not take any action that reasonably should be expected to cause Inotera to violate this Section 3.13.
(b)    Even if permitted under Section 9.4 of the Joint Venture Agreement, the Purchaser shall not, and shall cause its Affiliates not to, directly or indirectly recruit, solicit or hire, or make arrangements to recruit, solicit or hire, any current or former Segregated Employee during the Restriction Period.

DLI-266519827v1
18

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ARTICLE 4
PURCHASE AND SALE OF PRODUCTS
4.1    Product Quantity.  The Purchaser shall purchase from Inotera all of the Conforming Wafers manufactured in response to the Purchaser’s Demand Forecasts (including any adjusted Demand Forecast) in accordance with Article 3 and the Purchase Orders (including any revised or supplemented Purchase Order) accepted in accordance with this Article 4.
4.2    Non-Conforming Wafers.  At the direction and option of the Purchaser, Inotera shall deliver to the Purchaser all Non-Conforming Wafers produced by Inotera (a) from wafers designated from Wafer Start for the Purchaser in accordance with Section 2.4 and (b) in the case of Shared Design ID Wafers, the portion thereof allocated to the Purchaser in accordance with Section 2.4.  
4.3    Pre-Qual Wafers.  Notwithstanding anything herein to the contrary, to the extent requested in any Purchase Order placed, or any change order to a Purchase Order issued, by the Purchaser, Inotera shall manufacture and deliver Pre-Qual Wafers in lieu of Conforming Wafers; provided, however, that in no event shall Inotera be obligated to load any HMC Pre-Qual Wafers unless and until the Parties have first negotiated and agreed as to how to calculate the Price of HMC Pre-Qual Wafers as contemplated by Section 5.2(b).  Inotera shall promptly provide the Purchaser with full access to all data the Purchaser reasonably requests relating to Pre-Qual Wafers that are being manufactured by Inotera for the Purchaser.
4.4    Preliminary Price Notices; Placement of Purchase Orders.
(a)    Prior to each Fiscal Month, Inotera shall deliver to the Purchaser a notice (each, a “Preliminary Price Notice”), which shall set forth the Preliminary Price for Conforming Wafers, the Preliminary Price for Pre-Qual Wafers and the Preliminary Price for Non-Conforming Wafers for such Fiscal Month.  For the avoidance of doubt, prior to the Effective Date, Inotera shall deliver to the Purchaser a Preliminary Price Notice for the Fiscal Month commencing on the Effective Date.
(b)    Prior to each Fiscal Month, following receipt of the Preliminary Price Notice with respect to such Fiscal Month, the Purchaser shall place a non-cancelable blanket purchase order (each such order, a “Purchase Order”) for the quantity, by Design ID, of Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers to be supplied to it by Inotera in the upcoming Fiscal Month.  The Purchaser shall deliver to Inotera prior to the Effective Date Purchase Orders for the Fiscal Month commencing on the Effective Date.  The Purchaser may issue change orders to the Purchase Orders the Purchaser delivers to reflect changes in its Demand Forecasts in accordance with Article 3.  The Purchaser may also elect to place with Inotera out-of-cycle Purchase Orders of Conforming Wafers, Pre-Qual Wafers or Non-Conforming Wafers on an as-needed basis.  Any Purchase Order placed, or change order to a Purchase Order issued, hereunder shall be in writing and delivered via e-mail or facsimile transmission.  The terms and conditions of this Agreement supersede the terms and conditions contained in any sales or purchase documentation provided in connection herewith unless expressly agreed otherwise in a writing signed by the Parties.  Any 

DLI-266519827v1
19

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

Purchase Order for wafers may be placed in the name of the Purchaser, Micron or any other Affiliate of the Purchaser that is a direct or indirect wholly owned Subsidiary of Micron.  If a Purchase Order for wafers is placed in a name of an Affiliate of the Purchaser, the Purchaser shall be jointly and severally liable with such Affiliate for any and all responsibilities and obligations under the Purchase Order.
4.5    Content of Purchase Orders.  Each Purchase Order shall specify the following items:
(a)    the Purchase Order number;
(b)    the Design ID of each Conforming Wafer, Pre-Qual Wafer and Non-Conforming Wafer;
(c)    by Design ID, the forecasted quantity for the Fiscal Month of Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers;
(d)    the Preliminary Price for each Conforming Wafer, the Preliminary Price for each Pre-Qual Wafer and the Preliminary Price for each Non-Conforming Wafer;
(e)    the aggregate Preliminary Price for all Conforming Wafers ordered, the aggregate Preliminary Price for all Pre-Qual Wafers ordered and the aggregate Preliminary Price for all Non-Conforming Wafers ordered;
(f)    special instructions for manufacturing Pre-Qual Wafers, if any; and
(g)    other terms (if any).
Inotera shall not use or disclose the Purchaser Orders, or the contents thereof, received by Inotera in contravention of any Applicable Law.
4.6    Acceptance of Purchase Order.  Each Purchase Order that (a) corresponds to the then most-recently delivered Response to Forecast (and any revised Response to Forecast) delivered in accordance with Article 3 and (b) is otherwise free of errors, shall be deemed accepted by Inotera upon receipt and shall be binding on Inotera and the Purchaser to the extent not inconsistent with the then most-recently delivered Response to Forecast (or revised Response to Forecast).
4.7    Output Shortfall; Excess Output.
(a)    Inotera shall immediately notify the Purchaser in writing of any inability to meet a Purchase Order commitment to the Purchaser.  In such an event, the Purchaser shall accept delivery of such lesser quantities Inotera is able to ship and issue to Inotera a revised Purchase Order to account for such shortfall.

DLI-266519827v1
20

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(b)    Inotera shall immediately notify the Purchaser in writing if the output to be purchased by the Purchaser under this Agreement will exceed, for any Design ID, the quantity of Conforming Wafers, Pre-Qual Wafers or Non-Conforming Wafers contained in the Purchaser’s Purchase Order.  In such an event, the Purchaser shall accept delivery of the additional quantities and issue to Inotera a supplementary Purchase Order to cover such excess.
4.8    Taxes.
(a)    General.  All sales, use and other transfer taxes imposed directly on or solely as a result of the supplying of Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers to the Purchaser and the payments therefor provided herein shall be stated separately on Inotera’s Invoices, collected from the Purchaser and shall be remitted by Inotera to the appropriate tax authority (“Recoverable Taxes”), unless the Purchaser provides valid proof of tax exemption prior to the effective date of the transfer of the Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers or otherwise as permitted by Applicable Law prior to the time Inotera is required to pay such taxes to the appropriate tax authority.  When property is delivered and/or services are provided, or the benefit of services occurs, within jurisdictions in which collection of taxes from the Purchaser and remittance of taxes by Inotera is required by Applicable Law, Inotera shall have sole responsibility for payment of said taxes to the appropriate tax authorities.  In the event such taxes are Recoverable Taxes and Inotera does not collect tax from the Purchaser, or pay such taxes to the appropriate governmental entity on a timely basis, and is subsequently audited by any tax authority, liability of the Purchaser shall be limited to the tax assessment for such Recoverable Taxes with no reimbursement for penalty or interest charges or other amounts incurred in connection therewith.  Notwithstanding anything herein to the contrary, taxes other than Recoverable Taxes shall not be reimbursed by the Purchaser, and each of the Purchaser and Inotera is responsible for its own respective income taxes (including franchise and other taxes based on net income or a variation thereof), taxes based upon gross revenues or receipts and taxes with respect to general overhead, including business and occupation taxes, and such taxes shall not be Recoverable Taxes.
(b)    Withholding Taxes.  In the event that the Purchaser is prohibited by Applicable Law from making payments to Inotera unless the Purchaser deducts or withholds taxes therefrom and remits such taxes to the local taxing jurisdiction, then the Purchaser shall duly withhold and remit such taxes and shall pay to Inotera the remaining net amount after the taxes have been withheld.  Such taxes shall not be Recoverable Taxes and the Purchaser shall not reimburse Inotera for the amount of such taxes withheld.
4.9    Invoicing; Payment.
(a)    Along with each delivery of Conforming Wafers, Pre-Qual Wafers or Non-Conforming Wafers to the Purchaser, Inotera shall invoice the Purchaser for the aggregate Preliminary Price of the Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers contained in such delivery (a “Pro Forma Invoice”).

DLI-266519827v1
21

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(b)    No later than [***] days (or such other number of days as may be agreed in writing by the Parties) prior to the end of each Delivery Month, Inotera shall deliver to the Purchaser a statement setting forth Inotera’s estimates of JVC Per Design ID, Conforming Wafers JVC Per Design ID and Conforming Wafers JVC Per Wafer Per Node (as such terms are defined in Schedule 5.1(a)) for such Delivery Month.  No later than [***] days (or such other number of days as may be agreed in writing by the Parties) prior to the end of each Delivery Month, the Purchaser shall deliver to Inotera a statement setting forth the Purchaser’s estimates of the Price of Non-HMC Conforming Wafers for such Delivery Month and [***] Payment Amounts for such Delivery Month.
(c)    Within [***] Business Days (or such other number of days as may be agreed in writing by the Parties) after the delivery of the Purchaser Pricing Report, Inotera shall issue to the Purchaser a final invoice (a “Final Invoice”), which shall include a debit equal to the Price True-Up Amount for such Delivery Month, if positive, and a credit equal to the Price True‐Up Amount for such Delivery Month, if negative.
(d)    Except as otherwise specified in this Agreement, (i) the Purchaser shall pay Inotera for the amounts due and owing by, and duly invoiced in a Pro Forma Invoice to, the Purchaser within [***] days following delivery to the Purchaser of the Final Invoice for the Delivery Month in which such Pro Forma Invoice was delivered or, if longer, within [***] days following the end of such Delivery Month and (ii) the Purchaser shall pay Inotera for the amount due and owing by, and duly invoiced in a Final Invoice to, the Purchaser within [***] days following the delivery to the Purchaser of such Final Invoice or, if later, within [***] days following the end of the Delivery Month covered thereby.  All amounts owed under this Agreement are stated, calculated and shall be paid in United States Dollars.
(e)    If the Purchaser does not pay Inotera for the amounts due under this Agreement, interest on the unpaid invoiced amounts will be calculated and imposed at the rate of [***] percent ([***]%) per annum, on a daily basis, from the due date until the payment is made, provided that, if the due date falls on a day that is not a Business Day, the payment shall be due by the next succeeding Business Day.  However, if the Purchaser and Inotera do not agree on the payment amount of any Pro Forma Invoice or Final Invoice, interest on the disputed amount will not be imposed and accrued under this Agreement.  
(f)    In the event that the Purchaser reasonably disputes any Pro Forma Invoice or Final Invoice provided hereunder, the Purchaser and Inotera will each appoint an officer who will use their best efforts to resolve such dispute within [***] days following the date such dispute is raised by the Purchaser.  If such officers are unable to resolve the dispute in the given [***] days, then the dispute shall be submitted to the respective presidents of the Purchaser and Inotera for resolution.

DLI-266519827v1
22

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(g)    If this Agreement has terminated or is terminating so that the Purchaser will not be able to use any credits issued by Inotera to the Purchaser, Inotera will promptly pay to the Purchaser an amount equal to such credits.
4.10    Payment to Subcontractors.  Inotera shall be responsible for, and shall hold the Purchaser harmless from and against, any and all payments to the vendors or subcontractors Inotera utilizes in the performance of this Agreement.
4.11    Title; Risk of Loss.  Title to, and risk of loss of, Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers shall pass to the Purchaser [***] according to Incoterms 2010, as amended, provided that Inotera will [***], and will assist the Purchaser in [***] of, the Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers in a manner consistent with past practices.
4.12    Packaging.  All shipment packaging of the Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers shall be in conformance with the applicable Specifications, the Purchaser’s reasonable instructions and general industry standards, and shall be resistant to damage that may occur during transportation.  Marking on the packages shall be made by Inotera in accordance with the Purchaser’s reasonable instructions.
4.13    Shipment.  All Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers shall be prepared for shipment in a manner that:  (a) follows good commercial practice; (b) is acceptable to common carriers for shipment at the lowest rate; and (c) is adequate to ensure safe arrival.  Inotera shall mark all containers with (i) necessary lifting, handling and shipping information; (ii) Purchase Order number; (iii) date of shipment; and (iv) the name of the Purchaser.  If no instructions are given, Inotera shall select the most price effective carrier, given the time constraints known to Inotera.  In no event shall Inotera be obligated to maintain any significant inventory for the Purchaser.
4.14    Customs Clearance.  Upon the Purchaser’s request, Inotera shall promptly provide the Purchaser with a statement of origin, and applicable customs documentation, for Conforming Wafers, Pre-Qual Wafers and Non-Conforming Wafers wholly or partially manufactured outside of the country of import.
ARTICLE 5
PRICING
5.1    Price of Conforming Wafers.
(a)    The “Price” of each Non-HMC Conforming Wafer of a particular Design ID in any particular Delivery Month shall be calculated in accordance with Schedule 5.1(a).

DLI-266519827v1
23

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(b)    The “Price” of each HMC Conforming Wafer shall be calculated on a [***] basis to be negotiated in good faith by the Parties prior to Inotera loading any HMC Wafers.
(c)    The “Final Conforming Wafer Price” of each Non-HMC Conforming Wafer and HMC Conforming Wafer of a particular Design ID in any particular Delivery Month shall equal the quotient of (i) the sum of (A) the aggregate Price of all Non-HMC Conforming Wafers of such Design ID delivered to the Purchaser in such Delivery Month calculated in accordance with Section 5.1(a), plus (B) the aggregate Price of all HMC Conforming Wafers of such Design ID delivered to the Purchaser in such Delivery Month calculated in accordance with Section 5.1(b), plus (C) the [***] Payment Amount for such Design ID for such Delivery Month, if any, minus (D) the [***] for such Design ID for such Delivery Month, divided by (ii) the sum of (A) the number of Non-HMC Conforming Wafers of such Design ID delivered to the Purchaser in such Delivery Month plus (B) the number of HMC Conforming Wafers of such Design ID delivered to the Purchaser in such Delivery Month.
5.2    Price of Pre-Qual Wafers.
(a)    The “Price” of each Non-HMC Pre-Qual Wafer delivered to the Purchaser during a Delivery Month shall be calculated in accordance with Schedule 5.2 (a).
(b)    The “Price” of each HMC Pre-Qual Wafer shall be calculated on a [***] basis to be negotiated in good faith by the Parties prior to Inotera loading any HMC Wafers.
5.3    Price of Non-Conforming Wafers.  Any Non-Conforming Wafers delivered to the Purchaser during a Delivery Month shall be [***].
ARTICLE 6
VISITATIONS; FACTORY REPRESENTATIVES; AUDITS
6.1    Visits.  Inotera shall accommodate the Purchaser’s reasonable requests for visits to the Inotera Fab and for meetings for the purpose of reviewing performance of production of Conforming Wafers, including requests for further information and assistance in troubleshooting performance issues.  
6.2    Factory Representatives.  At Micron’s or the Purchaser’s request, Inotera will designate at least one (1) of its employees with sufficient knowledge of and expertise in the operation of the Inotera Fab to interface with Micron and the Purchaser in a manner consistent with past practices.  This employee will be the central point of contact for communication between Micron and the Purchaser, on the one hand, and Inotera, on the other hand, in regards to operational issues at the Inotera Fab arising out of the performance of this Agreement.  Such employee will enter into such confidentiality agreement as Micron or the Purchaser may reasonably require.  

DLI-266519827v1
24

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

6.3    Audit.  The Purchaser’s representatives and key customer representatives, upon the Purchaser’s request, shall be allowed to visit the Inotera Fab during normal working hours upon reasonable advance written notice to Inotera for the purposes of monitoring production processes and compliance with any requirements set forth in this Agreement applicable to the supply to the Purchaser and the applicable Specifications.  Upon completion of the audit, Inotera and the Purchaser shall agree to an audit closure plan, to be documented in the audit report issued by the Purchaser.
6.4    Financial Audit.  
(a)    Micron and the Purchaser reserve the right to have Inotera’s books and records related to pricing of the Conforming Wafers (including each of the components of Final Conforming Wafer Price) and Pre-Qual Wafers purchased by the Purchaser during both the then current Fiscal Year and the prior Fiscal Year inspected and audited not more than [***] during any Fiscal Year to ensure compliance with Article 3 and Article 5.  Such audit shall be performed, at the expense of Micron or the Purchaser, by an independent Third Party auditor acceptable to the Parties.  Micron and the Purchaser shall provide [***] days advance written notice to Inotera of their desire to initiate an audit, and the audit shall be scheduled so that it does not adversely impact or interrupt Inotera’s business operations.  If the audit reveals any material discrepancies, the Purchaser or Inotera shall reimburse the other, as applicable, for any material discrepancies within [***] days after completion of the audit.  The nature and extent of the discrepancies identified by the audit shall be reported to the Parties.  Notwithstanding the foregoing, auditor reports shall not disclose pricing, or terms of purchase, for any purchases of materials or equipment by Inotera, absent written agreement from the respective legal counsel of the Parties.  If any audit reveals a material discrepancy requiring a payment by Inotera, Micron and the Purchaser may increase the frequency of such audits to [***] for the [***].
(b)    Inotera reserves the right to have the books and records of Micron and the Purchaser related to the Purchaser Pricing Reports for both the then current Fiscal Year and the prior Fiscal Year inspected and audited not more than [***] during any Fiscal Year to ensure compliance with Article 5.  Such audit shall be performed, at Inotera’s expense, by an independent Third Party auditor acceptable to the Parties.  Inotera shall provide [***] days advance written notice to Micron and the Purchaser of its desire to initiate an audit, and the audit shall be scheduled so that it does not adversely impact or interrupt the business operations of Micron or the Purchaser.  If the audit reveals any material discrepancies, the Purchaser or Inotera shall reimburse the other, as applicable, for any material discrepancies within [***] days after completion of the audit.  The nature and extent of the discrepancies identified by the audit shall be reported to the Parties.  Notwithstanding the foregoing, auditor reports shall not disclose (i) [***] for [***] by Micron or the Purchaser, (ii) the back end [***] costs of Micron or the Purchaser, or (iii) the [***] ([***]) by Micron or the Purchaser, absent written agreement from the respective legal counsel of the Parties.  If any audit reveals a material discrepancy requiring a payment by the Purchaser, Inotera may increase the frequency of such audits to [***] for the [***].

DLI-266519827v1
25

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(c)    Information regarding the pricing of the Conforming Wafers (including each of the components of Final Conforming Wafer Price) and Pre-Qual Wafers purchased by the Purchaser and the Purchaser Pricing Reports as to which audit rights under this Section 6.4 have expired shall be deemed final and conclusive for all purposes (absent fraud or willful misconduct), except to the extent that (i) an audit with respect thereto has been commenced under this Section 6.4 prior to such expiration and (ii) the process under this Section 6.4 has not been fully completed with respect to such audit.  The Parties acknowledge the possibility that an audit commenced pursuant to this Section 6.4 for the then current Fiscal Year and the prior Fiscal Year may not be completed prior to [***].
ARTICLE 7
WARRANTY; HAZARDOUS SUBSTANCES; DISCLAIMER
7.1    Warranties.
(a)    Conforming Wafers.  Inotera makes the following warranties to the Purchaser of Conforming Wafers hereunder regarding the Conforming Wafers furnished to the Purchaser hereunder, which warranties shall survive any delivery, inspection, acceptance, payment or resale of such Conforming Wafers:
(i)    such Conforming Wafers conform to all applicable Specifications;
(ii)    such Conforming Wafers are free from defects in materials and workmanship; and
(iii)    Inotera has the necessary right, title and interest to such Conforming Wafers, and, upon the sale of such Conforming Wafers to the Purchaser, such Conforming Wafers shall be free of liens and encumbrances.
(b)    Pre-Qual Production Wafers.  Inotera makes the following warranties to the Purchaser of Pre-Qual Production Wafers hereunder regarding the Pre-Qual Production Wafers furnished to the Purchaser hereunder, which warranties shall survive any delivery, inspection, acceptance, payment or resale of such Pre-Qual Production Wafers:
(i)    such Pre-Qual Production Wafers are free from defects in materials and workmanship based on material and end product specifications provided by Micron; and
(ii)    Inotera has the necessary right, title and interest to such Pre-Qual Production Wafers, and, upon the sale of such Pre-Qual Production Wafers to the Purchaser, such Pre-Qual Production Wafers shall be free of liens and encumbrances.
(c)    Pre-Qual Engineering Wafers and Non-Conforming Wafers.  ALL PRE‐QUAL ENGINEERING WAFERS AND NON-CONFORMING WAFERS PROVIDED HEREUNDER ARE PROVIDED ON AN “AS IS,” “WHERE IS” BASIS WITH ALL FAULTS AND DEFECTS WITHOUT WARRANTY OF ANY KIND.

DLI-266519827v1
26

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

7.2    Warranty Claims.  Within a period of time, not to exceed the lesser of the actual warranty period applicable to the end customer for the DRAM Product at issue or [***] months from the date of the delivery of the Conforming Wafers or Pre-Qual Production Wafers at issue to the Purchaser, the Purchaser shall notify Inotera if it believes that any Conforming Wafer or Pre-Qual Production Wafer does not meet the warranty set forth in Section 7.1.  The Purchaser shall return such Conforming Wafer or Pre-Qual Production Wafer (or DRAM Product therefrom) to Inotera as directed by Inotera.  If a Conforming Wafer or Pre-Qual Production Wafer is determined not to be in compliance with such warranty, then the Purchaser shall be entitled to return such Conforming Wafer or Pre-Qual Production Wafer (or DRAM Product therefrom) and receive a credit (or, if this Agreement has terminated or is terminating so that it will not be able to use such credit, a refund) equal to the sum of (a) any monies paid to Inotera by the Purchaser in respect of such Conforming Wafer or Pre-Qual Production Wafer plus (b) any out-of-pocket charges for shipping and handling reasonably incurred by the Purchaser in connection with such Conforming Wafer or Pre-Qual Production Wafer.  THE FOREGOING REMEDY IS THE PURCHASER’S SOLE AND EXCLUSIVE REMEDY FOR INOTERA’S FAILURE TO MEET ANY WARRANTY OF SECTION 7.1.
7.3    Inspections.  The Purchaser may, upon reasonable advance written notice, request samples of WIP designated to the Purchaser (whether individually as contemplated by Section 2.4(b) or together with others as contemplated by Section 2.4(a)) during production for purposes of determining compliance with the requirements and applicable Specification(s) hereunder, provided that the provision of such samples shall not materially impact Inotera’s performance under the Manufacturing Plan or its ability to meet delivery requirements under any accepted Purchase Order.  Any samples provided hereunder shall be:  (a) limited in quantity to the amount reasonably necessary for the purposes hereunder; (b) invoiced and paid for in accordance with Section 4.9; and (c) included in any performance requirements.  Inotera shall provide reasonable assistance for the safety and convenience of the Purchaser in obtaining the samples in such manner as shall not unreasonably hinder or delay Inotera’s performance.
7.4    Hazardous Substances.
(a)    If Conforming Wafers, Pre-Qual Wafers, Non-Conforming Wafers or DRAM Products provided hereunder include Hazardous Substances as determined in accordance with Applicable Law, Inotera shall ensure that its employees, agents and subcontractors actually working with such materials in providing the Conforming Wafers, Pre-Qual Wafers, Non-Conforming Wafers or DRAM Products hereunder to the Purchaser are trained in accordance with Applicable Law regarding the nature of, and hazards associated with, the handling, transportation and use of such Hazardous Substances.
(b)    To the extent required by Applicable Law, Inotera shall provide the Purchaser with Material Safety Data Sheets (MSDS) either prior to or accompanying any delivery of Conforming Wafers, Pre-Qual Wafers, Non-Conforming Wafers or DRAM Products to the Purchaser.

DLI-266519827v1
27

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(c)    Inotera shall indemnify, defend and hold harmless the Purchaser from and against any and all Indemnified Losses suffered or incurred by the Purchaser based on, relating to, or arising under any Environmental Laws and related to the manufacture of Conforming Wafers, Pre-Qual Wafers, Non-Conforming Wafers or DRAM Products by Inotera.
7.5    Disclaimer.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE 7, INOTERA HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, NON-INFRINGEMENT OR OTHERWISE, WITH RESPECT TO THE CONFORMING WAFERS, PRE-QUAL WAFERS, NON-CONFORMING WAFERS OR DRAM PRODUCTS PROVIDED UNDER THIS AGREEMENT.  NO WARRANTIES SHALL APPLY TO ANY OF THE CONFORMING WAFERS, PRE-QUAL WAFERS, NON-CONFORMING WAFERS OR DRAM PRODUCTS THAT HAVE BEEN REPAIRED OR ALTERED, EXCEPT AS AUTHORIZED BY INOTERA, OR WHICH ARE SUBJECTED TO MISUSE, NEGLIGENCE, ACCIDENT OR ABUSE.  NO WARRANTIES FOR CONFORMING WAFERS, PRE-QUAL WAFERS, NON-CONFORMING WAFERS OR DRAM PRODUCTS DELIVERED BY INOTERA TO THE PURCHASER SHALL APPLY TO ANY WARRANTY CLAIM OR ISSUE OR DEFECT TO THE EXTENT CAUSED BY TECHNICAL MATERIALS PROVIDED OR SPECIFIED BY, THROUGH OR ON BEHALF OF THE PURCHASER, INCLUDING PRODUCT DESIGNS, TECHNOLOGY AND TEST PROGRAMS. 
ARTICLE 8
CONFIDENTIALITY; OWNERSHIP
8.1    Protection and Use of Confidential Information.  All information provided, disclosed or obtained by any Party in the performance of activities under this Agreement shall be subject to all applicable provisions of the Micron/Inotera Confidentiality Agreement.  Furthermore, the terms and conditions of this Agreement shall be considered “Confidential Information” under the Micron/Inotera Confidentiality Agreement for which each Party is considered a “Receiving Party” under such agreement.  To the extent there is a conflict between this Agreement and the Micron/Inotera Confidentiality Agreement, the terms of this Agreement shall control.
8.2    Masks for DRAM Products.  Any masks used by Inotera to manufacture DRAM Products under this Agreement shall be based on DRAM Designs owned by Micron or its Affiliates and shall be treated as “Confidential Information” of Micron under the Micron/Inotera Confidentiality Agreement.

DLI-266519827v1
28

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ARTICLE 9
INDEMNIFICATION
9.1    General Indemnity.  Subject to Article 10: 
(a)    Inotera shall indemnify, defend and hold harmless the Purchaser Indemnified Parties from and against any and all Indemnified Losses based on, or attributable to, any Third Party Claim, or threatened Third Party Claim, resulting from the negligence, gross negligence or willful misconduct of Inotera or any of its respective officers, directors, employees, agents or subcontractors.
(b)    the Purchaser shall indemnify, defend and hold harmless Inotera from and against any and all Indemnified Losses based on, or attributable to, any Third Party Claim, or threatened Third Party Claim, wherein the Third Party alleges that DRAM Products manufactured for and/or sold to the Purchaser by Inotera are infringing intellectual property rights of such Third Party.
9.2    Indemnification Procedures.
(a)    Promptly after the receipt by any Purchaser Indemnified Party or Inotera (an “Indemnified Party”) of a notice of any Third Party Claim that may be subject to indemnification under Section 9.1, such Indemnified Party shall give written notice of such Third Party Claim to the Party obligated to provide such indemnification under Section 9.1 (an “Indemnifying Party”), stating in reasonable detail the nature and basis of each allegation made in the Third Party Claim and the amount of potential Indemnified Losses with respect to each allegation, to the extent known, along with copies of the relevant documents received by the Indemnified Party evidencing the Third Party Claim and the basis for indemnification sought.  Failure of the Indemnified Party to give such notice shall not relieve the Indemnifying Party from liability on account of this indemnification, except if, and only to the extent that, the Indemnifying Party is actually prejudiced by such failure or delay.  Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, promptly after the Indemnified Party’s receipt thereof, copies of all notices and documents (including court papers) received by the Indemnified Party relating to the Third Party Claim.  The Indemnifying Party shall have the right to assume the defense of the Indemnified Party with respect to such Third Party Claim upon written notice to the Indemnified Party delivered within thirty (30) days after receipt of the particular notice from the Indemnified Party.  So long as the Indemnifying Party has assumed the defense of the Third Party Claim in accordance herewith and notified the Indemnified Party in writing thereof, (i) the Indemnified Party may retain separate co-counsel, at its sole cost and expense, and participate in the defense of the Third Party Claim, it being understood that the Indemnifying Party shall pay all reasonable costs and expenses of counsel for the Indemnified Party after such time as the Indemnified Party has notified the Indemnifying Party of such Third Party Claim and prior to such time as the Indemnifying Party has notified the Indemnified Party that it has assumed the defense of such Third Party Claim, (ii) the Indemnified Party shall not consent to the entry of any judgment or enter into any settlement with respect to a Third Party Claim without the prior written consent of the Indemnifying Party (not to be unreasonably withheld, conditioned or delayed) 

DLI-266519827v1
29

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

and (iii) the Indemnifying Party shall not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim (other than a judgment or settlement that is solely for money damages and is accompanied by a release of all indemnifiable claims against the Indemnified Party) without the prior written consent of the Indemnified Party (not to be unreasonably withheld, conditioned or delayed).
(b)    Equitable Remedies.  In the case of any Third Party Claim where the Indemnifying Party reasonably believes that it would be appropriate to settle such Third Party Claim using equitable remedies (i.e., remedies involving future activity of the Indemnified Party), the Indemnifying Party and the Indemnified Party shall work together in good faith to agree to a settlement; provided, however, that no Party shall be under any obligation to agree to any such settlement.
(c)    Treatment of Indemnification Payments; Insurance Recoveries.  Any indemnity payment under this Agreement shall be decreased by any amounts actually recovered by the Indemnified Party under Third Party insurance policies with respect to such Indemnified Losses (net of any premiums paid by such Indemnified Party under the relevant insurance policy).  Each Party agrees (i) to use all reasonable efforts to recover all available insurance proceeds and (ii) to the extent that any indemnity payment under this Agreement has been paid by the Indemnifying Party to the Indemnified Party prior to the recovery by the Indemnified Party of such insurance proceeds, the amount of such insurance proceeds actually recovered by the Indemnified Party shall be promptly paid to the Indemnifying Party.
(d)    Certain Additional Procedures.  The Indemnified Party shall cooperate and assist the Indemnifying Party in determining the validity of any Third Party Claim and in otherwise resolving such matters.  The Indemnified Party shall cooperate in the defense by the Indemnifying Party of each Third Party Claim (and the Indemnified Party and the Indemnifying Party agree with respect to all such Third Party Claims that a common interest privilege agreement exists between them), including:  (i) permitting the Indemnifying Party to discuss the Third Party Claim with such officers, employees, consultants and representatives of the Indemnified Party as the Indemnifying Party reasonably requests; (ii) providing to the Indemnifying Party copies of documents and samples of products as the Indemnifying Party reasonably requests in connection with defending such Third Party Claim; (iii) preserving all properties, books, records, papers, documents, plans, drawings, electronic mail and databases of the Indemnifying Party and relating to matters pertinent to the conduct of the Indemnifying Party under the Indemnified Party’s custody or control in accordance with such Party’s corporate documents retention policies, or longer to the extent reasonably requested by the Indemnifying Party; (iv) notifying the Indemnifying Party promptly of receipt by the Indemnified Party of any subpoena or other Third Party request for documents or interviews and testimony; (v) providing to the Indemnifying Party copies of any documents produced by the Indemnified Party in response to or compliance with any subpoena or other Third Party request for documents; and (vi) except to the extent inconsistent with the Indemnified Party’s obligations under Applicable Law and except to the extent that to do so would subject the Indemnified Party or its employees, agents or representatives to criminal or civil sanctions, unless ordered by a court to do 

DLI-266519827v1
30

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

otherwise, not producing documents to a Third Party until the Indemnifying Party has been provided a reasonable opportunity to review, copy and assert privileges covering such documents.
ARTICLE 10
LIMITATION OF LIABILITY
10.1    Damages Limitation.  SUBJECT TO SECTION 10.2, IN NO EVENT SHALL ANY PARTY BE LIABLE TO ANOTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR OTHER INDIRECT DAMAGES OR ANY PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT, WHETHER SUCH DAMAGES ARE BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
10.2    Exclusions.  Section 10.1 shall not apply to Section 7.4(c) or to any Party’s breach of Article 8.  
10.3    Mitigation.  Each Party shall have a duty to use commercially reasonable efforts to mitigate damages for which another Party is responsible.
ARTICLE 11
TERM AND TERMINATION
11.1    Term.
(a)    General.  The term of this Agreement (the “Term”) shall commence on the Effective Date and continue in effect until the second anniversary of the Effective Date, subject to potential extensions as contemplated below.  For the avoidance of doubt, in the event that the initial Term is not extended as contemplated below, the last day of the Term will be December 31, 2017, the first day of the Purchaser Wind-Down Period will be January 1, 2018 and the last day of the Purchaser Wind-Down Period will be December 31, 2020.
(b)    Process for Two-Year Extension.  During November 2016, officers appointed by the Parties shall hold one (1) or more meetings to discuss in good faith the potential extension of the Term by two (2) years, with such amendments to pricing and other terms as the Parties may mutually agree in writing.  If by the first day of December 2016 the Parties have not mutually agreed in writing to extend the Term by two (2) years, the matter shall be escalated to the president of Micron, acting on behalf of Micron and the Purchaser, and a designee of the Board of Directors of Inotera, acting on behalf of Inotera, who shall hold one (1) or more meetings to discuss in good faith the potential extension of the Term by two (2) years.  The meetings contemplated by this Section 11.1(b) shall be held on dates and by means, including remote communications, as agreed by the Parties.  For the avoidance of doubt, Micron and the Purchaser may condition their agreement to any extension contemplated by this Section 11.1(b) upon the adoption by the Board of Directors 

DLI-266519827v1
31

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

of Inotera of a Business Plan acceptable to Micron and the Purchaser covering the remaining Term as it would be extended by such agreement.
(c)    Process for Subsequent Extensions.  In the event that the Term is extended as contemplated by Section 11.1(b), during the month that is twenty-six (26) months prior to the end of the Term then in effect, officers appointed by the Parties shall hold one (1) or more meetings to discuss in good faith the potential extension of the Term by one (1) year, with such amendments to pricing and other terms as the Parties may mutually agree in writing.  If by the first day of the month that is twenty-five (25) months prior to the end of the Term then in effect the Parties have not mutually agreed in writing to extend the Term by one (1) year, the matter shall be escalated to the president of Micron, acting on behalf of Micron and the Purchaser, and a designee of the Board of Directors of Inotera, acting on behalf of Inotera, who shall hold one (1) or more meetings to discuss in good faith the potential extension of the Term by one (1) year.  The meetings contemplated by this Section 11.1(c) shall be held on dates and by means, including remote communications, as agreed by the Parties.  For the avoidance of doubt, Micron and the Purchaser may condition their agreement to any extension contemplated by this Section 11.1(c) upon the adoption by the Board of Directors of Inotera of a Business Plan acceptable to Micron and the Purchaser covering the remaining Term as it would be extended by such agreement.
(d)    Purchaser Wind-Down Period.  If (i) the Parties have not agreed to the two-year extension contemplated by Section 11.1(b) by first day of January 2017 or (ii) the Parties have not agreed to a one-year extension contemplated by Section 11.1(c) by the first day of the month that is twenty-four (24) months prior to the end of the Term then in effect (or, in each case,  such other date as may be agreed in writing by the Parties), the Term shall not be extended and, commencing immediately following the end of the Term there shall begin a three (3)-year wind-down period (the “Purchaser Wind-Down Period”) during which, on the pricing and other terms, and subject to the conditions, applicable under this Agreement immediately prior to the end of the Term, Inotera will supply to the Purchaser, and the Purchaser will purchase from Inotera, Conforming Wafers, Pre-Qual Wafers, and Non-Conforming Wafers, except that the Committed Purchaser Manufacturing Capacity shall be modified as set forth in Sections 11.1(e) and 11.1(f).  The Parties acknowledge that, during the Purchaser Wind-Down Period, Inotera may manufacture wafers or other products for one or more Persons other than the Purchaser, subject to Section 3.5.
(e)    [***] Reductions in Aggregate Committed Purchaser Manufacturing Capacity During the Purchaser Wind-Down Period.
(i)    During the [***] of the Purchaser Wind-Down Period, annualized aggregate Committed Purchaser Manufacturing Capacity across all Process Nodes installed at Inotera shall equal [***] percent ([***]%) of Inotera’s annualized aggregate Manufacturing Capacity across all Process Nodes that exists at the end of the Term (determined by annualizing the aggregate monthly Manufacturing Capacity across all Process Nodes installed at Inotera for the final Delivery Month of the Term). 

DLI-266519827v1
32

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(ii)    During the [***] of the Purchaser Wind-Down Period, annualized aggregate Committed Purchaser Manufacturing Capacity across all Process Nodes installed at Inotera shall equal a percentage of the annualized aggregate Committed Purchaser Manufacturing Capacity across all Process Nodes that exists at the end of the [***] of the Purchaser Wind-Down Period (determined by annualizing the aggregate monthly Committed Purchaser Manufacturing Capacity across all Process Nodes installed at Inotera for the final Delivery Month of the [***] of the Purchaser Wind-Down Period) selected by Inotera, which percentage shall be (A) equal to or less than [***] ([***]%) and (B) equal to or greater than [***] percent ([***]%) (provided that, if Inotera does not notify Micron and the Purchaser in writing of its selection at least [***] prior to the commencement of the [***] of the Purchaser Wind-Down Period, such percentage shall be [***] percent ([***]%)).
(iii)    During the [***] of the Purchaser Wind-Down Period, annualized aggregate Committed Purchaser Manufacturing Capacity across all Process Nodes installed at Inotera shall equal a percentage of the annualized aggregate Committed Purchaser Manufacturing Capacity across all Process Nodes that exists at the end of the [***] of the Purchaser Wind-Down Period (determined by annualizing the aggregate monthly Committed Purchaser Manufacturing Capacity across all Process Nodes installed at Inotera for the final Delivery Month of the [***] of the Purchaser Wind-Down Period) selected by Inotera, which percentage shall be (A) equal to or less than [***] ([***]%) and (B) equal to or greater than [***] percent ([***]%) (provided that, if Inotera does not notify Micron and the Purchaser in writing of its selection at least [***] prior to the commencement of the [***] of the Purchaser Wind-Down Period, such percentage shall be [***] percent ([***]%)).  
(f)    Process Node Allocation of Aggregate Committed Purchaser Manufacturing Capacity During the Purchaser Wind-Down Period.  Not later than [***] prior to the commencement of [***] of the Purchaser Wind-Down Period, the Purchaser shall provide a written notice (the “Process Node Allocation Notice”) to Inotera specifying, by Process Node, the quantity of Conforming Wafers Inotera will be required to manufacture utilizing such Process Nodes pursuant to this Agreement during such [***]; provided that (i) the quantity of Conforming Wafers for a particular Process Node may not exceed the aggregate Manufacturing Capacity of such Process Node for such [***] as specified in the Monthly Planning Statement delivered by Inotera immediately prior to the delivery of such Process Node Allocation Notice and (ii) the aggregate quantity of Conforming Wafers specified for all Process Nodes shall be equal to the aggregate Committed Purchaser Manufacturing Capacity for such [***], as determined in accordance with Section 11.1(e).  During [***] of the Purchaser Wind-Down Period, Inotera shall manufacture quantities of Conforming Wafers (or, if required pursuant to Section 4.3, Pre-Qual Wafers ordered in lieu thereof) in accordance with the applicable Process Node Allocation Notice, as such quantities may be modified pursuant to the terms of this Agreement.  

DLI-266519827v1
33

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

11.2    Termination.
(a)    Except as otherwise provided in this Section 11.2, this Agreement may not be terminated by any Party during either the Term or the Purchaser Wind-Down Period.
(b)    Notwithstanding anything herein to the contrary, upon the occurrence of an [***] (as defined in the Joint Venture Agreement), if [***] (as defined in the Joint Venture Agreement) within [***] (or such other period as the Purchaser may agree in writing) following the [***] and [***] shall have the right to terminate this Agreement effective upon written notice to [***], provided that [***].
(c)    Notwithstanding anything herein to the contrary, Micron and the Purchaser shall have the right to terminate this Agreement, effective upon written notice to Inotera, in the event that:  (i) Inotera files a petition under or otherwise seeks to take advantage of laws relating to bankruptcy, insolvency, suspension of payments, reorganization or rehabilitation, or makes a general assignment for the benefit of creditors, or otherwise acknowledges in writing insolvency, or is declared or adjudicated bankrupt or insolvent; (ii) Inotera commences a process of dissolution, liquidation or winding up; (iii) Inotera applies for or consents to the appointment of a trustee, receiver, administrator, custodian, liquidator or the like for itself or any substantial portion of its business or assets; or (iv) Inotera or any substantial portion of its business or assets involuntarily becomes the subject of any such filing, process or appointment and such involuntary filing, process or appointment is not stayed, rescinded, removed or otherwise eliminated within sixty (60) days.       
(d)    Notwithstanding anything herein to the contrary, this Agreement may be terminated:
(i)    by Inotera, effective upon written notice to Micron and the Purchaser, if there has been a material breach by Micron or the Purchaser of any material covenant or agreement contained in this Agreement and such breach has not been (A) cured by Micron or the Purchaser within thirty (30) days after written notice thereof from Inotera or (B) waived by Inotera; or
(ii)    by Micron and the Purchaser, effective upon written notice to Inotera, if there has been a material breach by Inotera of any material covenant or agreement contained in this Agreement and such breach has not been (A) cured by Inotera within thirty (30) days after written notice thereof from Micron and the Purchaser or (B) waived by Micron and the Purchaser.
(e)    Notwithstanding anything herein to the contrary, if prior to the Effective Date, the 2015 Supply Agreement is terminated other than as a result of the expiration of the term thereof on December 31, 2015, this Agreement shall automatically terminate and shall not become effective.

DLI-266519827v1
34

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

11.3    Inotera Requirements at Termination.  Within [***] days after (x) the end of the Purchaser Wind-Down Period or (y) the effectiveness of any termination of this Agreement pursuant to Section 11.2 (other than sub-section (e) thereof), Inotera:
(a)    shall deliver to Micron, or, pursuant to written instructions of Micron, destroy, all production masks obtained as contemplated by Section 2.3; and 
(b)    shall (i) deliver to Micron, or, pursuant to written instructions of Micron, destroy, all copies and other embodiments of any process technology or information provided to Inotera by Micron or its Affiliates, or any portion thereof, in whatever form received, reproduced or stored, (ii) if destruction is requested by Micron, certify to Micron and the Purchaser that such destruction is complete, and (iii) cease all use of the process technology or information provided to Inotera by Micron or its Affiliates.
11.4    Survival.  Termination of this Agreement shall not affect any of the Parties’ respective rights accrued, or obligations owed, before such termination.  In addition, (a) the following shall survive termination of this Agreement for any reason (other than termination pursuant to Section 11.2(e)), insofar as they relate to DRAM Products delivered by Inotera, or otherwise relate to the Parties’ respective performance of this Agreement, prior to such termination: Sections 2.7, 3.8, 3.10, 4.2, 4.5, 4.8, 4.9, 4.10, 4.11, 4.12, 4.13, 4.14, 6.4, 7.1, 7.2, 7.4(c) and 7.5 and Articles 5, 8, 9, 10 and 11 and (b) the following shall survive termination of this Agreement for any reason without limitation:  Sections 3.13, 4.10 and 7.4(c) and Articles 8 and 12.
ARTICLE 12
MISCELLANEOUS
12.1    Force Majeure Events.  The Parties shall be excused from any failure to perform any obligation hereunder to the extent such failure is caused by a Force Majeure Event. A Force Majeure Event shall operate to excuse a failure to perform an obligation hereunder only for the period of time during which the Force Majeure Event renders performance impossible or infeasible and only if the Party asserting Force Majeure as an excuse for its failure to perform has provided written notice to, in the event of an assertion by Micron or the Purchaser, Inotera and, in the event of an assertion by Inotera, Micron and the Purchaser specifying the obligation to be excused and describing the events or conditions constituting the Force Majeure Event. 
12.2    Specific Performance.  The Parties agree that irreparable damage will result if this Agreement is not performed in accordance with its terms, and the Parties agree that any damages available under the indemnification provisions or at law for a breach of this Agreement would not be an adequate remedy.  Therefore, the provisions hereof and the obligations of the Parties hereunder shall be enforceable in a court of equity, or other tribunal with jurisdiction, by a decree of specific performance, and appropriate injunctive relief may be applied for and granted in connection therewith.

DLI-266519827v1
35

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

12.3    Assignment.  This Agreement shall be binding upon and inure to the benefit of the successors and assigns of each Party hereto; provided, however, neither this Agreement nor any right or obligation hereunder may be assigned or delegated by any Party in whole or in part to any other Person without the prior written consent of the nonassigning Parties.  Any purported assignment in violation of the provisions of this Section 12.3 shall be null and void and have no effect.
12.4    Compliance with Laws and Regulations.  Each of the Parties shall comply with, and shall use reasonable efforts to require that its respective subcontractors comply with, Applicable Laws relating to this Agreement and the performance of such Party’s obligations hereunder.
12.5    Notice. All notices and other communications hereunder shall be in writing and shall be deemed given upon (a) transmitter’s confirmation of a receipt of a facsimile transmission, (b) confirmation of delivery by a standard overnight or recognized international carrier, or (c) delivery in person, addressed at the following addresses (or at such other address for a Party as shall be specified by like notice):
In the case of Micron: 
 
Micron Technology, Inc. 
8000 S. Federal Way 
Mail Stop 1-507 
Boise, ID  83716 
Attn:  General Counsel 
Facsimile:  (208) 368-1309
In the case of the Purchaser: 
 
Micron Semiconductor Asia Pte. Ltd. 
c/o Micron Technology, Inc. 
8000 S. Federal Way 
Mail Stop 1-507 
Boise, ID  83716 
Attn:  General Counsel 
Facsimile:  (208) 368-1309

DLI-266519827v1
36

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

In the case of Inotera: 
 
Inotera Memories, Inc. 
667, Fuhsing 3rd Road 
Hwa-Ya Technology Park 
Kueishan, Taoyuan 
Taiwan, R.O.C. 
Attn:  Director of Legal & IP Office 
Facsimile:  886-3-327-0037
12.6    Waiver.  The failure at any time of a Party to require performance by another Party of any responsibility or obligation required by this Agreement shall in no way affect a Party’s right to require such performance at any time thereafter, nor shall the waiver by a Party of a breach of any provision of this Agreement by another Party constitute a waiver of any other breach of the same or any other provision nor constitute a waiver of the responsibility or obligation itself.
12.7    Severability.  Should any provision of this Agreement be deemed in contradiction with the laws of any jurisdiction in which it is to be performed or unenforceable for any reason, such provision shall be deemed null and void, but this Agreement shall remain in full force and effect in all other respects.  Should any provision of this Agreement be or become ineffective because of changes in Applicable Laws or interpretations thereof, or should this Agreement fail to include a provision that is required as a matter of law, the validity of the other provisions of this Agreement shall not be affected thereby.  If such circumstances arise, the Parties shall negotiate in good faith appropriate modifications to this Agreement to reflect those changes that are required by Applicable Law.
12.8    Third Party Rights.  Except as expressly provided in Article 9, nothing in this Agreement, whether express or implied, is intended, or shall be construed, to confer, directly or indirectly, upon or give to any Person, other than the Parties hereto, any legal or equitable right, remedy or claim under or in respect of this Agreement or any covenant, condition or other provision contained herein.
12.9    Amendment.  This Agreement may not be modified or amended except by a written instrument executed by, or on behalf of, each of the Parties.
12.10    Entire Agreement.  This Agreement, together with the agreements and instruments expressly provided for herein (including the Micron/Inotera Confidentiality Agreement), constitute the entire agreement of the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral and written, among the Parties with respect to the subject matter hereof.
12.11    Choice of Law.  This Agreement shall be governed by and construed in accordance with the laws of the R.O.C., without giving effect to its conflict of laws principles.

DLI-266519827v1
37

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

12.12    Jurisdiction; Venue.  Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement shall be brought in the Taipei District Court, located in Taipei, Taiwan, and each of the Parties hereby consents and submits to the exclusive jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by Applicable Law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient forum.
12.13    Headings.  The headings of the Articles and Sections in this Agreement are provided for convenience of reference only and shall not be deemed to constitute a part hereof.
12.14    Counterparts.  This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
12.15    Insurance.  Without limiting or qualifying Inotera’s liabilities, obligations or indemnities otherwise assumed by Inotera pursuant to this Agreement, Inotera shall at all times (except as otherwise stipulated in Schedule 12.15), for so long as this Agreement remains in effect (and notwithstanding any termination of the Joint Venture Agreement), maintain in effect insurance of the types and in the amounts set forth on Schedule 12.15 or as otherwise agreed by the Parties from time to time.  Such insurance coverage may be provided through the coverage under one or more insurance policies maintained by Micron, NTC or any of their respective Affiliates.
12.16    Micron Undertaking.  Micron shall unconditionally cause the Purchaser to perform its obligations under this Agreement and hereby unconditionally guarantees the due performance of all such obligations by the Purchaser, including the payment of any amounts owing by the Purchaser under this Agreement.  Such guarantee is an independent obligation of Micron and upon any default by the Purchaser in the performance of its obligations, including the payment of any amounts owing by the Purchaser, under this Agreement, Inotera may immediately proceed against Micron without proceeding against the Purchaser or joining the Purchaser.
[SIGNATURE PAGES FOLLOW]

DLI-266519827v1
38

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

IN WITNESS WHEREOF, this Agreement has been duly executed by, and on behalf of, the Parties as of the Agreement Date.
	
			
	 
	MICRON TECHNOLOGY, INC.

	 
	By:
	/s/ Michael Sadler

	 
	 
	Name:  Michael Sadler

	 
	 
	Title:  VP Corp. Development

THIS IS A SIGNATURE PAGE FOR THE 
2016 SUPPLY AGREEMENT  
ENTERED INTO BY AND AMONG 
MICRON, THE PURCHASER AND INOTERA

DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
			
	 
	MICRON SEMICONDUCTOR ASIA PTE. LTD.

	 
	By:
	/s/ Lee Kok Choy

	 
	 
	Name:  Lee Kok Choy

	 
	 
	Title:  Director

THIS IS A SIGNATURE PAGE FOR THE 
2016 SUPPLY AGREEMENT  
ENTERED INTO BY AND AMONG 
MICRON, THE PURCHASER AND INOTERA

DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
			
	 
	INOTERA MEMORIES, INC.

	 
	By:
	 /s/ Chuan Lin   

	 
	 
	Name:  Chuan Lin

	 
	 
	Title: Independent Director

	 
	 
	 

THIS IS A SIGNATURE PAGE FOR THE 
2016 SUPPLY AGREEMENT  
ENTERED INTO BY AND AMONG 
MICRON, THE PURCHASER AND INOTERA

DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

SCHEDULE 1.1 – CERTAIN SPECIFICATIONS/QUALITY AND  
RELIABILITY STANDARDS AND CONTROL AND PROCESS MECHANISMS

Quality Conforming Material Requirements

		
	1)
	All DRAM Products shall have a lifetime of [***] or more as determined by reliability testing or a suitable proxy (“Reliability Testing”).  Inotera shall conduct such Reliability Testing, which shall include, but shall not be limited to, Fast Wafer Level Reliability (“FWLR”) tests for CHC and CHISEL and standard Slow Wafer Level Reliability (“SWLR”) tests for EM.

		
	2)
	In performing Reliability Testing, Inotera shall use specification limits and engineering limits provided by Micron and three sigma control limits with respect to measurement site level, unless otherwise specified by Micron.

		
	3)
	Inotera shall conduct, and monitor the results of, Reliability Testing in a manner consistent with the specification limits, engineering limits and control limits referred to in item 2 above and with respect to each measurement site, unless otherwise stated in Specifications.  If such Reliability Testing shows a failure of any such specification limit, engineering limit or control limit, Inotera will comply with a reaction plan specified by Micron.

		
	4)
	If an OOS event occurs, Inotera shall follow the OSAP procedure specified by Micron.  

		
	5)
	If an OOC event occurs, Inotera shall follow the OCAP procedure specified by Micron.  

		
	6)
	Inotera shall run corner lots through Reliability Testing, including, if applicable, any FWLR and SWLR tests, to develop, and test compliance with, specifications reasonably acceptable to Micron for inline steps that can cause degradation and will follow a disposition strategy reasonably acceptable to Micron if such specifications are not met. 

Schedule 1.1 – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

Final Probe Test Reliability Conformance Criteria
In testing reliability degradation mechanisms that can be tested via final probe suite, Inotera shall conduct such tests and shall use the wafer level specification limits listed in the table below.  Inotera shall monitor the results of probe testing around wafer level data, unless otherwise noted in Specifications.  Wafers exceeding such specification limits will be considered to be Non-Conforming Wafers.
Wafer average cutoffs for [***] DRAM 
(based on [***] Gb equivalent)

	
		
	Final Test Register
	Wafer Average Conformance Limit ([***] Gb equivalent)

	rdV
	[***]

	rdB
	[***]

	rdE
	[***]

	rdD
	[***]

	Rdt
	[***]

	rdT
	[***]

	rdC
	[***]

	Rdf
	[***]

Schedule 1.1 – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

SCHEDULE 3.10 – [***] PAYMENT AMOUNTS
1.[***] Payment Amount.  The Parties agree that the “[***] Payment Amount” with respect to a particular Design ID for any Delivery Month shall be calculated in the following manner:
“[***] Payment Amount” (D) = [***];
where the components of such calculation, and the related terms, have the meanings set forth below.  An example of the [***] Payment Amount calculation is set forth on Attachment 1 to this Schedule 3.10.  Each accounting term used in this Schedule 3.10 shall be applied in accordance with GAAP used in the United States or, if such term is not a GAAP accounting term, in accordance with Micron’s general accounting policies.
“A” = “[***] Revenue” = Micron’s consolidated net revenue in the Secondary Die Measurement Period associated with the sale [***] of Non-HMC DRAM Products (whether sold in die, wafer, packaged, module or subsequent form, but excluding DRAM Products contained on Multi-Chip Products) [***], determined on a particular Design ID basis;
“B” = “Purchaser Operating Expense Percentage” = for a Delivery Month that is the first, second or third fiscal month of Inotera commencing at least twenty (20) days following the end of a fiscal quarter of Micron, the quotient (expressed as a percentage and rounded to the nearest one-tenth) of (a) the sum of (i) Micron’s consolidated selling, general and administrative expense for such fiscal quarter of Micron, plus (ii) Micron’s consolidated research and development expense for such fiscal quarter of Micron, minus (iii) any [***] for such fiscal quarter of Micron, minus (iv) any [***] for such fiscal quarter of Micron, divided by (b) Micron’s consolidated net revenue for such fiscal quarter of Micron;
“C” = “[***] BEOL Costs” = the back end [***] costs incurred on a particular Design ID in the [***] Measurement Period by Micron and its consolidated Affiliates to produce Non-HMC DRAM Products in packaged, module or subsequent form (but not Multi-Chip Products) [***], including (a) [***] back end [***] and (b) [***] back end [***]; and 
“D” = “[***] Payment Amount” = [***].
Related Definitions.
“Micron SOW Expense” means, to the extent specified in a statement of work issued or entered into pursuant to arrangements between Inotera and Micron or one of its Affiliates not governed by this Agreement, any amounts for which Inotera invoices Micron or one of its Affiliates in connection with such statement of work.
“Micron SOW Revenue” means, to the extent specified in a statement of work issued or entered into pursuant to arrangements between Inotera and Micron or one of its Affiliates not governed by this Agreement, any amounts for which Micron or its Affiliates invoices or is permitted to invoice Inotera in connection with such statement of work.

Schedule 3.10 – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“[***]” means, for a particular Design ID, any die of such Design ID that [***] such die [***].
“[***] Measurement Period” means, for a particular Delivery Month, [***].

Schedule 3.10 – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ATTACHMENT 1 
TO 
SCHEDULE 3.10
EXAMPLE CALCULATION OF 
[***] PAYMENT AMOUNTS
See attached.

Attachment 1 to Schedule 3.10 – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
																				
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 3.10
Example Calculation of [***]

	 
	 
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]
	 
	[***]

	A
	[***] Revenue 
[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]

	B
	OPEX %
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	[***]%

	[***]
	Discounted [***] Revenue
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]

	C
	[***] BEOL Costs
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]

	[***]
	Net [***] Revenue
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]

	D[***]
	[***] Payment Amount
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	$
	[***]

Attachment 1 to Schedule 3.10 – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

SCHEDULE 5.1(a) - PRICE OF NON-HMC CONFORMING WAFERS
The Parties agree that the “Price” of each Non-HMC Conforming Wafer of a particular Design ID for any Delivery Month shall be calculated in the following manner.
“Price” of each Non-HMC Conforming Wafer (V) = Baseline Price Per Wafer Per Node (T) [***];
where the components of such calculation, and the related terms, have the meanings set forth below.  An example of the Price calculation is set forth on Attachment 1 to this Schedule 5.1.  Except as otherwise expressly provided herein, (a) each accounting term used in this Schedule 5.1 with respect to Micron shall be applied in accordance with GAAP used in the United States or if such term is not a GAAP accounting term, in accordance with Micron’s general accounting policies, and (b) each accounting term used in this Schedule 5.1 with respect to Inotera shall be applied in accordance with Taiwan GAAP or, if such term is not a Taiwan GAAP accounting term, in accordance with Inotera’s general accounting policies.  The calculation shall be made, and the Price shall be stated, in United States Dollars, with any components of such calculation that are initially stated in New Taiwan Dollars being converted to United States Dollars using the average during the applicable Delivery Month of the exchange rate quoted by such source as is regularly used by Inotera and identified by Inotera to Micron in writing.
1.    Baseline Price Per Wafer Per Node.  Baseline Price Per Wafer Per Node for any Delivery Month is (a) calculated as set forth below for each Process Node utilized by Inotera to manufacture Non-HMC Conforming Wafers for delivery to the Purchaser in such Delivery Month and (b) used in the calculation of the Price in such Delivery Month of Non-HMC Conforming Wafers of each Design ID manufactured using such Process Node.
“Baseline Price Per Wafer Per Node” (T) = Conforming Wafers JVC Per Wafer Per Node (Q) + Shared Margin Per Wafer Per Node (S) where the components of such calculation have the meanings set forth below:
“A” = “Worldwide DRAM Revenue Per Node” = Micron’s consolidated net revenue in the Measurement Period associated with the sale [***] of Non-HMC DRAM Products (whether sold in die, wafer, packaged, module or subsequent form, but excluding Non-HMC DRAM Products contained on Multi-Chip Products) produced from Prime Die manufactured using such Process Node, determined on a consolidated basis;
“B” = “Worldwide Multi-Chip Revenue Per Node” = Micron’s consolidated net revenue in the Measurement Period associated with the sale [***] of Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node, determined on a consolidated basis; 

Schedule 5.1(a) – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“C” = “[***] Multi-Chip Revenue Per Node” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node:  the product of (a) the quotient of (i) Micron’s consolidated net revenue in the Measurement Period associated with the sale [***] of [***] (whether sold in die, wafer, packaged, module or subsequent form, but excluding [***] Multi-Chip Products) produced from prime die [***], determined on a consolidated basis, divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] in the Measurement Period (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates during the Measurement Period;
“D” = “[***] Multi-Chip BEOL Costs Per Node” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node:  the product of (a) the quotient of (i) the aggregate back end [***] costs incurred in the Measurement Period by Micron and its consolidated Affiliates [***], including (I) [***] back end [***] and (II) [***] back end [***], divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] in the Measurement Period (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates during the Measurement Period; 
“E” = “[***] Worldwide Multi-Chip Revenue Per Node” = C - D;
“F” = “[***] Worldwide Multi-Chip Revenue Per Node” = B - E;
“G” = “Worldwide Revenue Per Node”  = A + F;
“H” = “Worldwide Revenue [***] Factor Per Node” = (W-Z)/Z;
“I” = “Adjusted Worldwide Revenue Per Node” = G x (1 + H);
“J” = “Purchaser Operating Expense Percentage” = for a Delivery Month that is the first, second or third fiscal month of Inotera commencing at least twenty (20) days following the end of a fiscal quarter of Micron, the quotient (expressed as a percentage and rounded to the nearest one-tenth) of (a) the sum of (i) Micron’s consolidated selling, general and administrative expense for such fiscal quarter of Micron, plus (ii) Micron’s consolidated research and development expense for such fiscal quarter of Micron, minus (iii) any [***] for such fiscal quarter of Micron, minus (iv) any [***] for such fiscal quarter of Micron, divided by (b) Micron’s consolidated net revenue for such fiscal quarter of Micron;
“K” = “Purchaser Operating Expense Per Node” = I x J;

Schedule 5.1(a) – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“L” = “Worldwide [***] Wafers [***] Per Node” = the sum of the following for each Design ID manufactured using such Process Node:  the quotient of (a) the number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products and Multi-Chip Products [***] Micron and its consolidated Affiliates in the Measurement Period, divided by (b) the average number of Prime Die per wafer of such Design ID manufactured [***] Micron and its consolidated Affiliates in the Measurement Period, [***], divided by (c) [***] for such Non-HMC DRAM Products in the Measurement Period;
“L1” = “[***]” = 1 – (L2 / (L2 + L3 + L4));
“L2” = “[***]” = the sum of (a) the difference of (i) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (iii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period plus (b) [***] during the Measurement Period, plus (c) [***] during the Measurement Period;
“L3” = “[***]” = the aggregate number of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period;
“L4” = “[***]” = the aggregate number of Prime Die of such Design ID [***] Multi-Chip Products during the Measurement Period;
“M” = “Adjusted Revenue Per Wafer Per Node” = (I-K)/L;
“N” = “Worldwide DRAM BEOL Costs Per Node” = the aggregate back end [***] costs incurred in the Measurement Period by Micron and its consolidated Affiliates to produce Non-HMC DRAM Products and Multi-Chip Products that contain such Non-HMC DRAM Products in packaged, module or subsequent form using the Prime Die manufactured using such Process Node, including (a) [***] back end [***] and (b) [***] back end [***];  
“O” = “Worldwide [***] Wafers [***] Per Node” = the sum of the following for each Design ID manufactured using such Process Node:  the quotient of (a) the sum of (i) the aggregate number of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period, plus (ii) the aggregate number of Prime Die of such Design ID contained on 

Schedule 5.1(a) – Page 3
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

Multi-Chip Products [***] for Micron and its consolidated Affiliates during the Measurement Period, divided by (b) the average number of Prime Die per wafer of such Design ID manufactured [***] Micron and its consolidated Affiliates in the Measurement Period, [***] divided by (c) [***] in the Measurement Period;
“P” = “BEOL Costs Per Wafer Per Node” = N/O;
“Q” = “[***] JVC Per Wafer Per Node” = for a particular Delivery Month, with respect to such Process Node, the quotient of (a) the sum of the [***] JVC Per Design ID (Q2) for each Design ID for which [***] manufactured using such Process Node were delivered to the Purchaser by Inotera in such Delivery Month, divided by (b) the number of [***] manufactured using such Process Node delivered to the Purchaser by Inotera in such Delivery Month.
“Q1” = “JVC Per Design ID” = for a particular Delivery Month, with respect to such Design ID, an amount equal to the sum of (a) the COGS [***] of such Design ID delivered to the Purchaser by Inotera in such Delivery Month, plus (b) the sum of (i) [***] such Design ID plus (ii) [***] such Design ID, in each case for such Delivery Month, plus (c) an amount equal to [***] with respect to such Design ID [***] in such Delivery Month [***], minus (d) the sum of (i) an amount equal to [***] with respect to such Design ID [***], plus (ii) any [***] such Design ID for such Delivery Month, plus (iii) any [***] such Design ID for such Delivery Month.
“Q2” = “[***] JVC Per Design ID” = for a particular Delivery Month, with respect to a particular Design ID, an amount equal to the difference of (a) the JVC Per Design ID (Q1) for such Delivery Month for such Design ID, minus (b) the sum of (i) [***] of Non-HMC Pre-Qual Wafers of such Design ID delivered to the Purchaser by Inotera in such Delivery Month plus (ii) [***] of HMC Wafers of such Design ID delivered to the Purchaser by Inotera in such Delivery Month.
“R” = “Margin Per Wafer Per Node” = M - P - Q;
“S” = “Shared Margin Per Wafer Per Node” = 0.5 x R;
“T” = “Baseline Price Per Wafer Per Node” = Q + S;
“U” = “[***] Per Wafer Per Design ID” = AY – AZ;
“V” = “Price of each Non-HMC Conforming Wafer”= T [***];
“W” = “Worldwide Revenue Per Wafer [***]” = G/L;
“X” = “[***] Worldwide Revenue Per Node” = X1 + X6;
“X1” = “[***] Worldwide DRAM Revenue Per Node” = Micron’s consolidated net revenue [***] associated with the sale [***] of Non-HMC DRAM Products (whether sold in die, wafer, packaged, module or subsequent form, but excluding Non-HMC DRAM Products contained 

Schedule 5.1(a) – Page 4
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

on Multi-Chip Products) produced from Prime Die manufactured using such Process Node, determined on a consolidated basis; 
“X2” = “[***] Revenue Per Node” = Micron’s consolidated net revenue in the Measurement Period associated with the sale [***] of Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node, determined on a consolidated basis,
“X3” = “[***] Multi-Chip Revenue Per Node” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node:  the product of (a) the quotient of (i) Micron’s consolidated net revenue [***] associated with the sale [***] of [***] (whether sold in die, wafer, packaged, module or subsequent form, but excluding [***] Multi-Chip Products) produced from prime die [***], determined on a consolidated basis, divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates [***];
“X4” = “[***] BEOL Costs Per Node” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die manufactured using such Process Node:  the product of (a) the quotient of (i) the aggregate back end [***] costs incurred [***] by Micron and its consolidated Affiliates [***] including (I) [***] back end [***] and (II) [***] back end [***], divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates [***];
“X5” = “[***] Worldwide Multi-Chip Revenue Per Node” = X3 - X4;
“X6” = “[***] Worldwide Multi-Chip Revenue Per Node” = X2 - X5;
“Y” = “[***] Worldwide [***] Wafers [***] Per Node” = the sum of the following for each Design ID manufactured using such Process Node:  the quotient of (a) the number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products and Multi-Chip Products [***] Micron and its consolidated Affiliates [***], divided by (b) the average number of Prime Die per wafer of such Design ID manufactured [***] Micron and its consolidated Affiliates [***], divided by (c) [***] for such Non-HMC DRAM Products [***];
“Y1” = “[***]” = 1 – (Y2 / (Y2 + Y3 + Y4));  

Schedule 5.1(a) – Page 5
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Y2” = “[***]” = the sum of (a) the difference of (i) the aggregate number of Prime Die of such Design ID [***] for Micron and its consolidated Affiliates [***], minus (ii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***], minus (iii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] plus (b) [***] plus (c) [***];
“Y3” = “[***]” = the aggregate number of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***];
“Y4” = “[***]” = the aggregate number of Prime Die of such Design ID [***] Multi-Chip Products [***]; and
“Z” = “[***] Worldwide Revenue Per Wafer [***]” = X/Y.
2.    [***] Per Wafer Per Design ID. [***] Per Wafer Per Design ID for any Delivery Month is calculated for each Design ID as described below; provided, however, that the [***] Per Wafer Per Design ID will be [***] for a particular Design ID for a particular Delivery Month if either (i) the Inotera Average [***] Wafers Probed for such Design ID for such Delivery Month is [***], (ii) the Micron Average [***] Wafers Probed for such Design ID for such Delivery Month is [***], or (iii) the Inotera Average [***] Wafers Probed for such Design ID for such Delivery Month is [***] for such Design ID for such Delivery Month.
“[***] Per Wafer Per Design ID” (U) = [***] Per Wafer (AY) – [***] Per Wafer (AZ);
where the components of such calculation have the meanings set forth below.
“AA” = “Worldwide DRAM Revenue Per Design ID” = Micron’s net revenue in the Measurement Period associated with the sale [***] of Non-HMC DRAM Products (whether sold in die, wafer, packaged, module or subsequent form, [***]) produced from Prime Die of such Design ID, determined on a consolidated basis;
“AB” = “Worldwide Multi-Chip Revenue Per Design ID” = Micron’s net revenue in the Measurement Period associated with the sale [***] of Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die of such Design ID, determined on a consolidated basis; 
“AC” = “[***] Multi-Chip Revenue Per Design ID” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die of such Design ID:  the product of (a) the quotient of (i) Micron’s net revenue in the Measurement Period associated with the sale [***] of [***] (whether sold in die, wafer, packaged, module or subsequent form, but excluding [***] Multi-Chip Products) produced from prime die [***] 

Schedule 5.1(a) – Page 6
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

determined on a consolidated basis, divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] in the Measurement Period (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates during the Measurement Period;
“AD” = “[***] Multi-Chip BEOL Costs Per Design ID” = the sum of the following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced from Prime Die of such Design ID:  the product of (a) the quotient of (i) the aggregate back end [***] costs incurred in the Measurement Period by Micron and its consolidated Affiliates [***], including (I) [***] back end [***] and (II) [***] back end [***], divided by (ii) the number of prime die [***] Micron and its consolidated Affiliates [***] in the Measurement Period (but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die [***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates during the Measurement Period;
“AE” = “[***] Worldwide Multi-Chip Revenue Per Design ID” = AC - AD;
“AF” = “[***] Worldwide Multi-Chip Revenue Per Design ID” = AB - AE;
“AG” = “Worldwide Revenue Per Design ID”  = AA + AF;
“AH” = “Adjusted Worldwide Revenue Per Design ID” = AG x (1 + H);
“AI” = “Purchaser Operating Expense Per Design ID” = AH x J;
“AJ” = “Worldwide Die [***] Per Design ID” = the number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products and Multi-Chip Products [***] Micron and its consolidated Affiliates [***] in the Measurement Period;
“AK” = “[***] Average Prime Die Per Conforming Wafer” = the average number of Prime Die per Non-HMC Conforming Wafer of such Design ID [***] in the Measurement Period [***];
“AL” = “[***]” = 1 – (AL1 / (AL1 + AL2 + AL3));
“AL1” = “[***]” = the sum of (a) the difference of (i) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (iii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period, plus (b) [***] during the Measurement Period, plus (c) [***] during the Measurement Period;

Schedule 5.1(a) – Page 7
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“AL2 = “[***]” = the aggregate number of Prime Die of such Design ID [***] contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID [***] contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period;
“AL3” = “[***]” = the aggregate number of Prime Die of such Design ID [***] Multi-Chip Products during the Measurement Period;
“AM” = “[***] Per Wafer” = ((AH - AI)/AJ) x AK x AL;
“AN” = “[***] Average Prime Die Per Wafer” = the average number of Prime Die per wafer of such Design ID [***] Micron and its consolidated Affiliates in the Measurement Period, [***];
“AO” = “[***]” = 1 – (AO1 / (AO1 + AO2 + AO3));  
“AO1” = “[***]” = the sum of (a) the difference of (i) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates [***] the Measurement Period, minus (iii) the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period plus (b) [***] during the Measurement Period, plus (c) [***] during the Measurement Period;
“AO2” = “[***]” = the aggregate number of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period;
“AO3” = “[***]” = the aggregate number of Prime Die of such Design ID [***] Multi-Chip Products during the Measurement Period;
“AP” = “[***] Per Wafer” = ((AH - AI)/AJ) x AN x AO;

Schedule 5.1(a) – Page 8
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“AQ” = “Worldwide DRAM BEOL Costs Per Design ID” = the aggregate back end [***] costs incurred in the Measurement Period by Micron and its consolidated Affiliates to produce Non-HMC DRAM Products and Multi-Chip Products that contain such Non-HMC DRAM Products in packaged, module or subsequent form using the Prime Die of such Design ID, including (a) [***] back end [***] and (b) [***] back end [***]; 
“AR” = “Worldwide Die [***] Per Design ID” = the sum of (i) the aggregate number of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent form, excluding Prime Die of such Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated Affiliates during the Measurement Period, plus (ii) the aggregate number of Prime Die of such Design ID contained on Multi-Chip Products [***] for Micron and its consolidated Affiliates during the Measurement Period;
“AS” = “[***] BEOL Costs Per Wafer” = (AQ/AR) x AK x AL;
“AT” = “[***] BEOL Costs Per Wafer” = (AQ/AR) x AN x AO; 
“AU” = “[***] JVC Per Design ID” = for a particular Delivery Month, with respect to a particular Design ID, an amount equal to the [***] JVC Per Design ID (Q2).
“AV” = “[***] Per Design ID” = with respect to a particular Design ID, the number of Prime Die from Non-HMC Conforming Wafers [***] in a particular Delivery Month, [***];
“AW” = “[***]” = (AU/AV) x AK x AL;
“AX” = “[***]” = (AU/AV) x AN x AO;
“AY” = “[***] Per Wafer” = AW + (0.5x (AM - AS - AW)); and
“AZ” = “[***] Per Wafer” = AX + (0.5x (AP - AT - AX)).
3.    Related Definitions.
“COGS” means Inotera’s cost of goods sold, including [***] but, for the avoidance of doubt, excluding [***] and also excluding (a) any [***], (b) any costs or expenses (i) associated with [***] or (ii) otherwise [***], and (c) any [***].
“Inotera Average [***] Wafers Probed” means, with respect to a particular Design ID for a particular Delivery Month, an amount equal to the quotient of (a) the number of Non-HMC Conforming Wafers, [***], of such Design ID delivered to the Purchaser by Inotera that are subjected to Probe Testing [***], divided by (b) the [***].

Schedule 5.1(a) – Page 9
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

“Inotera SOW Expense” means, to the extent specified in a statement of work issued or entered into pursuant to arrangements between Inotera and Micron or one of its Affiliates not governed by this Agreement, any amounts for which Micron or one of its Affiliates invoices Inotera in connection with such statement of work (excluding any such amounts that relate solely to the purchase of wafers by Inotera from Micron or one of its Affiliates).
“Inotera SOW Revenue” means, to the extent specified in a statement of work issued or entered into pursuant to arrangements between Inotera and Micron or one of its Affiliates not governed by this Agreement, any amounts for which Inotera invoices or is permitted to invoice Micron or one of its Affiliates in connection with such statement of work.
“Measurement Period” means, for a particular Delivery Month, the three most recently completed fiscal months of Micron including such Delivery Month.
“Micron Average [***] Wafers Probed” means, with respect to a particular Design ID for a particular Delivery Month, an amount equal to the quotient of (a) the number of conforming wafers, [***], containing Non-HMC DRAM Products of such Design ID manufactured by or for Micron and its Affiliates [***] that are subjected to probe testing [***] divided by (b) the [***].
“Micron Fab Network Average [***] Wafers Probed” means, with respect to a particular Design ID for a particular Delivery Month, an amount equal to the quotient of (a) the number of conforming wafers, as determined immediately after probe testing, containing Non-HMC DRAM Products of such Design ID manufactured [***] Micron and its Affiliates that are subjected to probe testing [***], divided by (b) the [***].
“Multi-Chip Product” means [***].
“[***]” means[***].
“[***]” means [***].
“[***]” means[***].
“Prime Die” means, for a particular Design ID, a die that meets the applicable Specifications for such Design ID immediately after Probe Testing and immediately after final back-end testing.
“[***]” means, for a particular Delivery Month, [***].

Schedule 5.1(a) – Page 10
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

4.    Adjustments to Price Calculation.  
(a)    Use of Proxy for First [***] of a New Non-HMC DRAM Product.  In connection with the calculation of the Price of a Non-HMC Conforming Wafer of a particular Design ID for a particular Delivery Month, if any Non-HMC DRAM Product of a particular Design ID affecting such calculation has not generated revenue (in the case of Non-HMC DRAM Products) for all or a portion of the [***] immediately preceding Delivery Months, then the Parties shall work together in good faith to determine the adjustments, based on the use of the best available proxy consistent with historical practices of the Parties, as are necessary or appropriate to accomplish the intent and purpose of the inclusion of the “Measurement Period” and [***] concepts in this Schedule 5.1.
(b)    Grace Period for First Non-HMC DRAM Product on a New Process Node.  With respect to the first Design ID of Non-HMC DRAM Product to be manufactured on a newly installed Process Node at the Inotera Fab, the Price of Non-HMC Conforming Wafers of such Design ID for the first [***] after qualification of such Design ID shall be the Baseline Price Per Wafer for such Design ID, and the [***] for such [***] period shall be disregarded and deemed not to exist in calculating Price of Non-HMC Conforming Wafers of such Design ID after such [***] period.
(c)    Use of Proxy Where Data Not Available for [***].  In connection with the calculation of the Price of a Non-HMC Conforming Wafer of a particular Design ID for a particular Delivery Month, if any [***] affecting such calculation has not generated revenue for all or a portion of the [***] immediately preceding Delivery Months, then the Parties shall work together in good faith to determine the adjustments, based on the use of the best available proxy, as are necessary or appropriate to accomplish the intent and purpose of the calculation of [***] Worldwide Multi-Chip Revenue Per Node[***] Worldwide Multi-Chip Revenue Per Node[***] Worldwide Multi-Chip Revenue Per Design ID[***] and [***] Worldwide Multi‐Chip Revenue Per Design ID[***] in this Schedule 5.1.
(d)    Adjustment for [***] of Non-HMC DRAM Products.  Notwithstanding anything herein to the contrary, if (i) Micron and its consolidated Affiliates are unable to sell into any particular premium market a proportion of the Non-HMC DRAM Products contained on Non-HMC Conforming Wafers delivered to the Purchaser by Inotera under this Agreement at least equal to the proportion of Non-HMC DRAM Products contained on wafers manufactured by or for Micron and its consolidated Affiliates at other fabs in the Micron Fab Network that are sold into such premium market, and (ii) Inotera is [***], then sales into such premium market by Micron and its consolidated Affiliates will be excluded from the calculation of Price of Non-HMC Conforming Wafers, including Micron’s consolidated net revenue associated therewith, the number of Prime Die of such Non-HMC DRAM Products sold and a proportionate share of the back end [***] costs associated therewith ([***]back end [***]).

Schedule 5.1(a) – Page 11
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

(e)    Adjustment to Pricing of HMC Conforming Wafers and HMC Pre-Qual Wafers.  If by [***] the Parties have not reached an agreement with respect to [***] pricing for HMC Conforming Wafers and HMC Pre-Qual Wafers as contemplated by Section 5.1(b) and Section 5.2(b), then from [***] forward, the Parties agree that a proportion of HMC DRAM Product for any particular Process Node shall be included into the detailed calculation of the Price of Non-HMC Conforming Wafers for such Process Node stated in this Schedule 5.1(a); provided, however, such proportion of HMC DRAM Product to be included shall be limited to [***] .
Statement of Intent and Agreement: 
The purpose of the above Section 5(e) is to memorialize the fundamental intent and agreement of the Parties that when this Section 5(e) is applicable, the calculation components of a proportion of HMC DRAM Product for any particular Process Node shall be included in determining the Price of Non-HMC Conforming Wafers for such Process Node.  Apart from when and how much HMC DRAM Product revenue to include in the Price calculation (about which the Parties hereby acknowledge they have reached complete agreement and for which no further negotiation is necessary or appropriate), the Parties also recognize that other portions of the Non-HMC Conforming Wafers Price calculation (for example, [***] and [***]) cannot be finally concluded until the exact nature of the HMC DRAM Products is known. Therefore, the Parties hereby agree that before the time this Section 5(e) becomes applicable, they will negotiate in good faith such portions of the Price formula not already definitely agreed.  Given that [***], the Parties hereby agree the negotiation referenced in the previous sentence will be guided by and consistent with the pricing methodology already agreed with respect to Multi-Chip Products.

Schedule 5.1(a) – Page 12
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ATTACHMENT 1 
TO SCHEDULE 5.1(a)
EXAMPLE CALCULATIONS OF  
NON-HMC CONFORMING WAFER PRICE
See attached.

Attachment 1 to Schedule 5.1(a) – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
													
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a)
Example Calculation of Baseline Price

	 
	 
	 
	[***]
	 
	 
	 
	 
	 
	 
	[***]
	 
	 

	A
	WW DRAM Revenue per Node
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	B
	WW MCP Revenue per Node
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	C
	[***] MCP Revenue
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	D
	[***] MCP BEOL Cost
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	E=C-D
	[***] WW MCP Revenue per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	F=B-E
	[***] WW MCP Revenue per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	G=A+F
	WW Revenue per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	H
	WW Revenue [***] Factor per Node
	 
	[***]%
	 
	 
	 
	 
	 
	 
	[***]%
	 
	 

	I=G*(1+H)
	Adj WW Revenue per Node
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	J
	OPEX %
	 
	[***]%
	 
	 
	 
	 
	 
	 
	[***]%
	 
	 

	K=I*J
	Purchaser Operating Expense
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	L
	WW [***] Wafer [***] per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	M=(I-K)/L
	Adjusted Revenue Per Wafer Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	N
	WW DRAM BEOL Costs Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	O
	WW [***] Wafers [***] per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	P=N/O
	BEOL Costs Per Wafer Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	Q
	[***] JVC per Wafer Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	R=M-P-Q
	Margin per Wafer Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	S=R*.5
	Shared Margin Per Wafer Per Node
	$
	[***] 
	 
	 
	 
	 
	 
	$
	[***]
	 
	 

	T=Q+S
	Baseline Price Per Wafer Per Node
	$
	[***]
	 
	 
	 
	 
	 
	$
	[***] 
	 
	 

	 
	 
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	U
	[***] Per Wafer Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	V=T[***]
	Price
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

Attachment 1 to Schedule 5.1(a) – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
						
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a)
Example Calculation of Worldwide Revenue [***] Factor per Node

	 
	 
	 
	[***]
	 
	[***]

	 
	 
	 
	 
	 
	 

	G
	WW Revenue per Node
	$
	[***]
	$
	[***]

	L
	WW [***] Wafer [***] per Node
	 
	[***]
	 
	[***]

	W=G/L
	WW Revenue per Wafer [***]
	$
	[***]
	$
	[***]

	X=[***]
	[***] WW Revenue per Node
	$
	[***]
	$
	[***]

	Y=[***]
	[***] WW [***] Wafer [***] per Node
	 
	[***]
	 
	[***]

	Z=X/Y
	[***] WW Revenue per Wafer [***]
	$
	[***]
	$
	[***]

	H=(W-Z)/Z
	WW Revenue [***] Factor per Node
	 
	[***]%
	 
	[***]%

Attachment 1 to Schedule 5.1(a) – Page 3
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
			
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a)
Example of Purchaser Operating Expense Percentage Calculation

	Net Sales
	$
	[***]

	SG&A
	$
	[***]

	R&D
	$
	[***]

	Total Operating Expense
	$
	[***]

	Adjustments:
	 
	 

	[***]
	$
	[***]

	[***]
	$
	[***]

	Adjusted Operating Expense
	$
	[***]

	Purchaser Operating Expense Percentage
	 
	[***]%

Attachment 1 to Schedule 5.1(a) – Page 4
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
																							
	Micron Technology, Inc. & Inotera Memories, Inc
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a) and Schedule 5.2(a)
Example JVC Cost Report

	 
	x-rate:
	[***] 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	Shipment by category (Wafer):
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Conforming wafers
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual Wafers
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Total shipment
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Shipment by category (Die):
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	%
	[***]%
	[***]%
	[***]
	[***]%
	[***]%
	[***]%
	[***]
	[***]
	[***]

	 
	[***]
	Die
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	JV Costs:
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	(A) JVC
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment: 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Q1
	JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	JVC per wafer
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	(B) Pre-Qual wafers JVC
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment:
	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual JVC per Wafer
	US$
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	(A)-(B)-(C)
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment:
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Q2
	Conforming JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	Q
	Conforming JVC per Wafer
	US$
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	IMI actual cost breakdown:
	 
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

Attachment 1 to Schedule 5.1(a) – Page 5
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
																			
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a) and Schedule 5.2 (a)
Example[***]

	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	[***]

	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 

Attachment 1 to Schedule 5.1(a) – Page 6
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
															
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a)
Example Calculation of [***] Per Wafer

	 
	 
	[***]
	[***]

	 
	 
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AA
	WW DRAM Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AB
	WW MCP Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AC
	[***] MCP Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AD
	[***] MCP BEOL Cost Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AE=AC-AD
	[***] WW MCP Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AF=AB-AE
	[***] WW MCP Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AG=AA+AF
	WW Revenue Per Design ID
	$
	[***]
	 
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	H
	WW Revenue [***] Factor Per Node
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	 
	[***]%
	 
	[***]%

	AH=AG*(1+H)
	Adjusted WW Revenue Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	J
	OPEX %
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	 
	[***]%
	 
	[***]%

	AI=AH*J
	Purchaser Operating Expense Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AJ
	WW Die Sold Per DiD
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AK
	[***] Average Prime Die Per Conforming Wafer
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AL
	[***]
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	 
	[***]%
	 
	[***]%

	AM=(AH-AI)/AJ*AK*AL
	[***] per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AN
	[***] Average Prime Die per Wafer
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AO
	[***]
	 
	[***]%
	 
	[***]%
	 
	[***]%
	 
	 
	[***]%
	 
	[***]%

	AP=(AH-AI)/AJ*AN*AO
	[***] per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AQ
	WW DRAM BEOL Cost Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AR
	WW Die [***] Per DiD
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AS=AQ/AR*AK*AL
	[***] BEOL Cost per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AT=AQ/AR*AN*AO
	[***] BEOL Cost per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AU
	[***] JVC Per Design ID
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AV
	[***] Per Design ID
	 
	[***]
	 
	[***]
	 
	[***]
	 
	 
	[***]
	 
	[***]

	AW=AU/AV*AK*AL
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AX=AU/AV*AN*AO
	[***]
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AY=AW+(.50*(AM-AS-AW)
	[***] per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	AZ=AW+(.50*(AP-AT-AX)
	[***] per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	U=AY-AZ
	[***] per Wafer
	$
	[***]
	$
	[***]
	$
	[***]
	 
	$
	[***]
	$
	[***]

Attachment 1 to Schedule 5.1(a) – Page 7
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

SCHEDULE 5.2(a) – PRICE OF NON-HMC PRE-QUAL WAFERS
The Parties agree that the “Price” of each Non-HMC Pre-Qual Wafer of a particular Design ID for any Delivery Month shall be an amount equal to the product of (a) [***] and (b) an amount equal to the quotient of (i) the JVC Per Design ID (as defined in Schedule 5.1(a)) of such Non-HMC Pre-Qual Wafers of such Design ID for such Delivery Month, divided by (ii) the number of Non-HMC Pre-Qual Wafers of such Design ID delivered to the Purchaser by Inotera in such Delivery Month.

Schedule 5.2(a) – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

ATTACHMENT 1 
TO SCHEDULE 5.2(a)
EXAMPLE CALCULATIONS OF  
NON-HMC PRE-QUAL WAFER PRICE
See attached.

Attachment 1 to Schedule 5.2(a) – Page 1
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
																							
	Micron Technology, Inc. & Inotera Memories, Inc
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a) and Schedule 5.2(a)
Example JVC Cost Report

	 
	x-rate:
	[***] 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	Shipment by category (Wafer):
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Conforming wafers
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual Wafers
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Total shipment
	PCS
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Shipment by category (Die):
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	%
	[***]%
	[***]%
	[***]
	[***]%
	[***]%
	[***]%
	[***]
	[***]
	[***]

	 
	[***]
	Die
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	JV Costs:
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	(A) JVC
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment: 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Q1
	JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	JVC per wafer
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	(B) Pre-Qual wafers JVC
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment:
	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Pre-Qual JVC per Wafer
	US$
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	(A)-(B)-(C)
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM shipping COGS
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	DRAM Operating Expenses
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	Adjustment:
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	HMC wafers JVC
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Q2
	Conforming JVC
	NTD
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	Q
	Conforming JVC per Wafer
	US$
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	IMI actual cost breakdown:
	 
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	 
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	NTD
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 
	 

Attachment 1 to Schedule 5.2(a) – Page 2
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

	
																			
	Micron Technology, Inc. & Inotera Memories, Inc.
2016 Supply Agreement
Attachment 1 to Schedule 5.1 (a) and Schedule 5.2 (a)
Example [***]

	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	[***]

	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	 
	[***]
	 
	 
	 
	 
	 
	 
	 
	 

Attachment 1 to Schedule 5.2(a) – Page 3
DLI-266519827v1 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

CONFIDENTIAL

SCHEDULE 12.15 - INSURANCE
1.    Property Insurance:  All risk property insurance, including earth movement and flood insurance, insuring against physical damage on a replacement cost basis for assets, and insuring against resultant business interruption from physical damage on an actual-loss sustained basis. Such property insurance limit will be not less than [***] for [***] and not less than [***] for other covered losses. (Note: limits shared with NTC).  It is acknowledged that: (1) such coverage for “production related equipment” is based on “replacement cost basis;” and (2) non-production related assets (such as buildings, facilities, and other non-production equipment) are insured under “actual cash value” and such coverage is subject to monthly adjustment depending on the actual cash value.
2.    Liability Insurance:
A.    Commercial general liability insurance (also known as public liability insurance) coverage for bodily injury and property damage liability, with a limit of not less than [***] for each loss occurrence and not less than [***] in annual aggregate coverage.
B.    Automobile liability coverage for bodily injury and property damage liability with a limit of not less than [***] for each loss occurrence and not less than [***] in annual aggregate coverage for owned, hired, and non-owned automobiles.
3.    Employers Liability: Employers’ liability coverage that is included in the Labor Insurance Program or other equivalent program required under the Applicable Laws of the R.O.C.

Schedule 12.15 – Page 1
DLI-266519827v12015 Q2 EX 10-92 2007 Equity Incentive Plan

EXHIBIT 10.92

MICRON TECHNOLOGY, INC.
AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN

ARTICLE 1
PURPOSE

1.1.    GENERAL.  The purpose of the Micron Technology, Inc. Amended and Restated 2007 Equity Incentive Plan (the "Plan") is to promote the success, and enhance the value, of Micron Technology, Inc. (the "Company"), by linking the personal interests of employees, non-employee directors and consultants of the Company or any Affiliate (as defined below) to those of Company shareholders and by providing such persons with an incentive for outstanding performance.  The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of employees, non-employee directors and consultants upon whose judgment, interest, and special effort the successful conduct of the Company's operation is largely dependent.  Accordingly, the Plan permits the grant of incentive awards from time to time to selected employees, non-employee directors and consultants of the Company and its Affiliates; provided, however, that no Corporate Officer is eligible to be a Participant in the Plan.

ARTICLE 2
DEFINITIONS

2.1.    DEFINITIONS.  When a word or phrase appears in this Plan with the initial letter capitalized, and the word or phrase does not commence a sentence, the word or phrase shall generally be given the meaning ascribed to it in this Section or in Section 1.1 unless a clearly different meaning is required by the context.  The following words and phrases shall have the following meanings:

(a)    "Affiliate" means (i) any Subsidiary or Parent, or (ii) an entity that directly or through one or more intermediaries controls, is controlled by or is under common control with, the Company, as determined by the Committee.

(b)    "Award" means any Option, Stock Appreciation Right, Restricted Stock Award, Restricted Stock Unit Award, Deferred Stock Unit Award, Performance Share, Other Stock-Based Award, or any other right or interest relating to Stock or cash, granted to a Participant under the Plan.

(c)    "Award Certificate" means a written document, in such form as the Committee prescribes from time to time, setting forth the terms and conditions of an Award.  Award Certificates may be in the form of individual award agreements or certificates or a program document describing the terms and provisions of an Awards or series of Awards under the Plan.  The Committee may provide for the use of electronic, internet or other non-paper Award Certificates, and the use of electronic, internet or other non-paper means for the acceptance thereof and actions thereunder by a Participant.

(d)    "Board" means the Board of Directors of the Company.

(e)    "Change in Control" means and includes the occurrence of any one of the following events:

1

(i)    individuals who, on the Effective Date, constitute the Board of Directors of the Company (the "Incumbent Directors") cease for any reason to constitute at least a majority of such Board, provided that any person becoming a director after the Effective Date and whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to the election or removal of directors ("Election Contest") or other actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board ("Proxy Contest"), including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest, shall be deemed an Incumbent Director; or

(ii)    any person is or becomes a "beneficial owner" (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of either (A) 35% or more of the then-outstanding shares of common stock of the Company ("Company Common Stock") or (B) securities of the Company representing 35% or more of the combined voting power of the Company's then outstanding securities eligible to vote for the election of directors (the "Company Voting Securities"); provided, however, that for purposes of this subsection (ii), the following acquisitions shall not constitute a Change in Control: (w) an acquisition directly from the Company, (x) an acquisition by the Company or a Subsidiary of the Company, (y) an acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary of the Company, or (z) an acquisition pursuant to a Non-Qualifying Transaction (as defined in subsection (iii) below); or

(iii)    the consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or a Subsidiary (a "Reorganization"), or the sale or other disposition of all or substantially all of the Company's assets (a "Sale") or the acquisition of assets or stock of another corporation (an "Acquisition"), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the outstanding Company Common Stock and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Reorganization, Sale or Acquisition (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets or stock either directly or through one or more subsidiaries, the "Surviving Corporation") in substantially the same proportions as their ownership, immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any Subsidiary of the Company, (y) the Surviving Corporation or its ultimate parent corporation, or (z) any employee benefit plan or related trust) sponsored or maintained by any of the foregoing is the beneficial owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Corporation, and (C) at least a majority of the members of the board of directors of the Surviving Corporation were Incumbent Directors at the time of the Board's approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a "Non-Qualifying Transaction"); or

(iv)    approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.

2

(f)    "Code" means the Internal Revenue Code of 1986, as amended from time to time.  Reference to a specific Section of the Code or regulation thereunder shall include such Section or regulation, any valid regulation promulgated under such Section, and any comparable provision of any future law, legislation or regulation amending, supplementing or superseding such Section or regulation. 

(g)    "Committee" means the committee of the Board described in Article 4.

(h)    "Company" means Micron Technology, Inc., a Delaware corporation, or any successor corporation.

(i)    "Continuous Status as a Participant" means the absence of any interruption or termination of service as an employee, officer, consultant or non-employee director of the Company or any Affiliate, as applicable; provided, however, that for purposes of an Incentive Stock Option, or a Stock Appreciation Right issued in tandem with an Incentive Stock Option, "Continuous Status as a Participant" means the absence of any interruption or termination of service as an employee of the Company or any Parent or Subsidiary, as applicable, pursuant to applicable tax regulations.  Continuous Status as a Participant shall not be considered interrupted in the case of any leave of absence authorized in writing by the Company prior to its commencement; provided, however, that for purposes of Incentive Stock Options, no such leave may exceed 90 days, unless reemployment upon expiration of such leave is guaranteed by statute or contract.  If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, on the 91st day of such leave any Incentive Stock Option held by the Participant shall cease to be treated as an Incentive Stock Option and shall be treated for tax purposes as a Nonstatutory Stock Option.

(j)    "Corporate Officer" means an officer of the Company whose compensation is approved by the Compensation Committee of the Board, including without limitation the Chief Executive Officer of the Company.

(k)    "Covered Employee" means a covered employee as defined in Code Section 162(m)(3).

(l)    "Disability" or "Disabled" has the same meaning as provided in the long-term disability plan or policy maintained by the Company or if applicable, most recently maintained, by the Company or if applicable, an Affiliate, for the Participant, whether or not such Participant actually receives disability benefits under such plan or policy.  If no long-term disability plan or policy was ever maintained on behalf of Participant or if the determination of Disability relates to an Incentive Stock Option, or a Stock Appreciation Right issued in tandem with an Incentive Stock Option, Disability means Permanent and Total Disability as defined in Section 22(e)(3) of the Code.  Notwithstanding the foregoing, for any Awards that constitute a nonqualified deferred compensation plan within the meaning of Section 409A(d) of the Code, Disability has the meaning given such term in Section 409A of the Code.  In the event of a dispute, the determination whether a Participant is Disabled will be made by the Committee and may be supported by the advice of a physician competent in the area to which such Disability relates.

(m)    "Deferred Stock Unit" means a right granted to a Participant under Article 11.

(n)    "Dividend Equivalent" means a right granted with respect to an Award, as provided in Article 12.

(o)    "Effective Date" has the meaning assigned such term in Section 3.1.

(p)    "Eligible Participant" means an employee, consultant or non-employee director of the Company or any Affiliate; provided, however, that no Corporate Officer is eligible to be a Participant in the Plan.

3

(q)    "Exchange" means the New York Stock Exchange or any other national securities exchange or national market system on which the Stock may from time to time be listed or traded. 

(r)    "Fair Market Value" of the Stock, on any date, means: (i) if the Stock is listed or traded on any Exchange, the closing price for such Stock (or the closing bid, if no sales were reported) as quoted on such Exchange (or the Exchange with the greatest volume of trading in the Stock) for the last market trading day prior to the day of determination, as reported by Bloomberg L.P. or such other source as the Committee deems reliable; (ii) if the Stock is quoted on the over-the-counter market or is regularly quoted by a recognized securities dealer, but selling prices are not reported, the Fair Market Value of the Stock shall be the mean between the high bid and low asked prices for the Stock on the last market trading day prior to the day of determination, as reported by Bloomberg L.P. or such other source as the Committee deems reliable, or (iii) in the absence of an established market for the Stock, the Fair Market Value shall be determined by such other method as the Committee determines in good faith to be reasonable and in compliance with Code Section 409A.

(s)    "Full Value Award" means an Award other than in the form of an Option or SAR, and which is settled by the issuance of Stock (or at the discretion of the Committee, settled in cash valued by reference to Stock value).

(t)    "Grant Date" of an Award means the first date on which all necessary corporate action has been taken to approve the grant of the Award as provided in the Plan, or such later date as is determined and specified as part of that authorization process.  Notice of the grant shall be provided to the grantee within a reasonable time after the Grant Date.

(u)    "Incentive Stock Option" means an Option that is intended to be an incentive stock option and meets the requirements of Section 422 of the Code or any successor provision thereto.

(v)    "Non-Employee Director" means a director of the Company who is not a common law employee of the Company or an Affiliate.

(w)    "Nonstatutory Stock Option" means an Option that is not an Incentive Stock Option.

(x)    "Option" means a right granted to a Participant under Article 7 of the Plan to purchase Stock at a specified price during specified time periods.  An Option may be either an Incentive Stock Option or a Nonstatutory Stock Option.

(y)    "Other Stock-Based Award" means a right, granted to a Participant under Article 13 that relates to or is valued by reference to Stock or other Awards relating to Stock.

(z)    "Parent" means a corporation, limited liability company, partnership or other entity which owns or beneficially owns a majority of the outstanding voting stock or voting power of the Company.  Notwithstanding the above, with respect to an Incentive Stock Option, Parent shall have the meaning set forth in Section 424(e) of the Code.

(aa)    "Participant" means a person who, as an employee, non-employee director or consultant of the Company or any Affiliate, has been granted an Award under the Plan; provided that in the case of the death of a Participant, the term "Participant" refers to a beneficiary designated pursuant to Section 14.5 or the legal guardian or other legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court supervision.  Notwithstanding the foregoing, a Participant shall not include any Corporate Officer of the Company.

(bb)    "Performance Share" means any right granted to a Participant under Article 9 to a unit to be valued by reference to a designated number of Shares to be paid upon achievement of such performance goals as the Committee establishes with regard to such Performance Share.

4

(cc)    "Person" means any individual, entity or group, within the meaning of Section 3(a)(9) of the 1934 Act and as used in Section 13(d)(3) or 14(d)(2) of the 1934 Act.

(dd)    "Plan" means the Micron Technology, Inc. Amended and Restated 2007 Equity Incentive Plan, as amended from time to time.

(ee)    "Qualified Performance-Based Award" means an Award that is either (i) intended to qualify for the Section 162(m) Exemption and is made subject to performance goals based on Qualified Business Criteria as set forth in Section 14.10(b), or (ii) an Option or SAR.

(ff)    "Qualified Business Criteria" means one or more of the Business Criteria listed in Section 14.10(b) upon which performance goals for certain Qualified Performance-Based Awards may be established by the Committee.

(gg)    "Restricted Stock Award" means Stock granted to a Participant under Article 10 that is subject to certain restrictions and to risk of forfeiture.

(hh)    "Restricted Stock Unit Award" means the right granted to a Participant under Article 10 to receive shares of Stock (or the equivalent value in cash or other property if the Committee so provides) in the future, which right is subject to certain restrictions and to risk of forfeiture.

(ii)    "Section 162(m) Exemption" means the exemption from the limitation on deductibility imposed by Section 162(m) of the Code that is set forth in Section 162(m)(4)(C) of the Code or any successor provision thereto.

(jj)    "Shares" means shares of the Company's Stock.  If there has been an adjustment or substitution pursuant to Section 15.1, the term "Shares" shall also include any shares of stock or other securities that are substituted for Shares or into which Shares are adjusted pursuant to Section 15.1.

(kk)    "Stock" means the $.10 par value common stock of the Company and such other securities of the Company as may be substituted for Stock pursuant to Article 15.

(ll)    "Stock Appreciation Right" or "SAR" means a right granted to a Participant under Article 8 to receive a payment equal to the difference between the Fair Market Value of a Share as of the date of exercise of the SAR over the base price of the SAR, all as determined pursuant to Article 8.

(mm)    "Subsidiary" means any corporation, limited liability company, partnership or other entity of which a majority of the outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company.  Notwithstanding the above, with respect to an Incentive Stock Option, Subsidiary shall have the meaning set forth in Section 424(f) of the Code.

(nn)    "1933 Act" means the Securities Act of 1933, as amended from time to time.

(oo)    "1934 Act" means the Securities Exchange Act of 1934, as amended from time to time.

5

ARTICLE 3
EFFECTIVE TERM OF PLAN

3.1.    EFFECTIVE DATE.  The Plan shall be effective as of the date it is approved by the shareholders of the Company (the "Effective Date").

3.2.    TERMINATION OF PLAN.  Unless earlier terminated as provided herein, the Plan shall continue in effect until the tenth anniversary of the Effective Date or, if the shareholders approve an amendment to the Plan that increases the number of Shares subject to the Plan, the tenth anniversary of the date of such approval.  The termination of the Plan on such date shall not affect the validity of any Award outstanding on the date of termination, which shall continue to be governed by the applicable terms and conditions of the Plan.  No Incentive Stock Options may be granted more than ten years after the earlier of (a) adoption of this Plan by the Board, or (b) the Effective Date.

ARTICLE 4
ADMINISTRATION

4.1.    COMMITTEE.  The Plan shall be administered by a Committee appointed by the Board (which Committee shall consist of at least two directors) or, at the discretion of the Board from time to time, the Plan may be administered by the Board.  It is intended that at least two of the directors appointed to serve on the Committee shall be "non-employee directors" (within the meaning of Rule 16b-3 promulgated under the 1934 Act) and "outside directors" (within the meaning of Code Section 162(m)) and that any such members of the Committee who do not so qualify shall abstain from participating in any decision to make or administer Awards that are made to Eligible Participants who at the time of consideration for such Award (i) are persons subject to the short-swing profit rules of Section 16 of the 1934 Act, or (ii) are reasonably anticipated to become Covered Employees during the term of the Award.  However, the mere fact that a Committee member shall fail to qualify under either of the foregoing requirements or shall fail to abstain from such action shall not invalidate any Award made by the Committee which Award is otherwise validly made under the Plan.  The members of the Committee shall be appointed by, and may be changed at any time and from time to time in the discretion of, the Board.  Unless and until changed by the Board, the Compensation Committee of the Board is designated as the Committee to administer the Plan.  The Board may reserve to itself any or all of the authority and responsibility of the Committee under the Plan or may act as administrator of the Plan for any and all purposes.  To the extent the Board has reserved any authority and responsibility or during any time that the Board is acting as administrator of the Plan, it shall have all the powers of the Committee hereunder, and any reference herein to the Committee (other than in this Section 4.1) shall include the Board.  To the extent any action of the Board under the Plan conflicts with actions taken by the Committee, the actions of the Board shall control.

4.2.    ACTION AND INTERPRETATIONS BY THE COMMITTEE.  For purposes of administering the Plan, the Committee may from time to time adopt rules, regulations, guidelines and procedures for carrying out the provisions and purposes of the Plan and make such other determinations, not inconsistent with the Plan, as the Committee may deem appropriate.  The Committee's interpretation of the Plan, any Awards granted under the Plan, any Award Certificate and all decisions and determinations by the Committee with respect to the Plan are final, binding, and conclusive on all parties.  Each member of the Committee is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other employee of the Company or any Affiliate, the Company's or an Affiliate's independent certified public accountants, Company counsel or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.

4.3.    AUTHORITY OF COMMITTEE.  Except as provided below, the Committee has the exclusive power, authority and discretion to:

(a)    Grant Awards;

(b)    Designate Participants;

6

(c)    Determine the type or types of Awards to be granted to each Participant;

(d)    Determine the number of Awards to be granted and the number of Shares or dollar amount to which an Award will relate;

(e)    Determine the terms and conditions of any Award granted under the Plan, including but not limited to, the exercise price, base price, or purchase price, any restrictions or limitations on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations or waivers thereof, based in each case on such considerations as the Committee in its sole discretion determines;

(f)    Accelerate the vesting, exercisability or lapse of restrictions of any outstanding Award, in accordance with Article 14, based in each case on such considerations as the Committee in its sole discretion determines;

(g)    Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an Award may be paid in, cash, Stock, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered;

(h)    Prescribe the form of each Award Certificate, which need not be identical for each Participant;

(i)    Decide all other matters that must be determined in connection with an Award;

(j)    Establish, adopt or revise any rules, regulations, guidelines or procedures as it may deem necessary or advisable to administer the Plan;

(k)    Make all other decisions and determinations that may be required under the Plan or as the Committee deems necessary or advisable to administer the Plan;

(l)    Amend the Plan or any Award Certificate as provided herein; and

(m)    Adopt such modifications, procedures, and subplans as may be necessary or desirable to comply with provisions of the laws of the United States or any non-U.S. jurisdictions in which the Company or any Affiliate may operate, in order to assure the viability of the benefits of Awards granted to participants located in such other jurisdictions and to meet the objectives of the Plan.

Notwithstanding the foregoing, grants of Awards to Non-Employee Directors hereunder shall be made only in accordance with the terms, conditions and parameters of a plan, program or policy for the compensation of Non-Employee Directors as in effect from time to time, and the Committee may not make discretionary grants hereunder to Non-Employee Directors.

    

7

Notwithstanding the above, the Board may, by resolution, expressly delegate to a special committee, consisting of one or more directors who may but need not be officers of the Company, the authority, within specified parameters as to the number and terms of Awards, to (i) designate officers, employees and/or consultants of the Company or any of its Affiliates to be recipients of Awards under the Plan, and (ii) to determine the number of such Awards to be received by any such Participants; provided, however, that such delegation of duties and responsibilities to an officer of the Company may not be made with respect to the grant of Awards to eligible participants (a) who are subject to Section 16(a) of the 1934 Act at the Grant Date, or (b) who as of the Grant Date are reasonably anticipated to be become Covered Employees during the term of the Award.  The acts of such delegates shall be treated hereunder as acts of the Board and such delegates shall report regularly to the Board and the Committee regarding the delegated duties and responsibilities and any Awards so granted.

4.4.    AWARD CERTIFICATES.  Each Award shall be evidenced by an Award Certificate.  Each Award Certificate shall include such provisions, not inconsistent with the Plan, as may be specified by the Committee.

ARTICLE 5
SHARES SUBJECT TO THE PLAN

5.1.    NUMBER OF SHARES.  Subject to adjustment as provided in Sections 5.2 and 15.1, the aggregate number of Shares reserved and available for issuance pursuant to Awards granted under the Plan shall be 135,000,000; provided, however, that each Share issued under the Plan pursuant to a Full Value Award that is settled in Stock shall reduce the number of available Shares by two (2) shares.  The maximum number of Shares that may be issued upon exercise of Incentive Stock Options granted under the Plan shall be 2,000,000.

5.2.    SHARE COUNTING.  Shares covered by an Award shall be subtracted from the Plan share reserve as of the date of grant, but shall be added back to the Plan share reserve in accordance with this Section 5.2.

(a)    To the extent that an Award is canceled, terminates, expires, is forfeited or lapses for any reason, any unissued or forfeited Shares originally subject to the Award will be added back to the Plan share reserve and again be available for issuance pursuant to Awards granted under the Plan.

(b)    Shares subject to Awards settled in cash will be added back to the Plan share reserve and again be available for issuance pursuant to Awards granted under the Plan.

(c)    Substitute Awards granted pursuant to Section 14.14 of the Plan shall not count against the Shares otherwise available for issuance under the Plan under Section 5.1.

(d)    The following shares of Stock may not again be made available for issuance as Awards under the Plan: (i) shares of Stock not issued or delivered as a result of the net settlement of an outstanding Option or SAR, (ii) shares of Stock used to pay the exercise price or withholding taxes related to an outstanding Option or SAR, or (iii) shares of Stock repurchased on the open market with the proceeds of the exercise price of an Option.

5.3.    STOCK DISTRIBUTED.  Any Stock distributed pursuant to an Award may consist, in whole or in part, of authorized and unissued Stock, treasury Stock or Stock purchased on the open market.

5.4.    LIMITATION ON AWARDS.  Notwithstanding any provision in the Plan to the contrary (but subject to adjustment as provided in Section 15.1), the maximum number of Shares with respect to one or more Options and/or SARs that may be granted during any one calendar year under the Plan to any one Participant shall be 5,000,000.  The maximum aggregate grant with respect to Awards of Restricted Stock, Restricted Stock Units, Deferred Stock Units, Performance Shares or other Stock-Based Awards (other than Options or SARs) granted in any one calendar year to any one Participant shall be 5,000,000.
    

8

5.5    MINIMUM VESTING REQUIREMENTS.  Except in the case of substitute Awards granted pursuant to Section 14.14, Full-Value Awards granted under the Plan to an Eligible Participant shall either (i) be subject to a minimum vesting period of three years (which may include graduated vesting within such three-year period), or one year if the vesting is based on performance criteria other than continued service, or (ii) be granted solely in exchange for foregone cash compensation.  Notwithstanding the foregoing, (i) the Committee may at its discretion permit and authorize acceleration of vesting of such Full-Value Awards in the event of the Participant's death, Disability, or retirement, or the occurrence of a Change in Control (subject to the requirements of Article 11 in the case of Qualified Performance-Based Awards), and (ii) the Committee may grant Full-Value Awards without the above-described minimum vesting requirements, or may permit and authorize acceleration of vesting of Full-Value Awards otherwise subject to the above-described minimum vesting requirements, with respect to Awards  covering five percent (5%) or fewer of the total number of Shares authorized under the Plan.

ARTICLE 6
ELIGIBILITY

6.1.    GENERAL.  Awards may be granted only to Eligible Participants; except that Incentive Stock Options may be granted to only to Eligible Participants who are employees of the Company or a Parent or Subsidiary as defined in Section 424(e) and (f) of the Code.  Eligible Participants who are service providers to an Affiliate may be granted Options or SARs under this Plan only if the Affiliate qualifies as an "eligible issuer of service recipient stock" within the meaning of §1.409A-1(b)(5)(iii)(E) of the final regulations under Code Section 409A.

ARTICLE 7
STOCK OPTIONS

7.1.    GENERAL.  The Committee is authorized to grant Options to Participants on the following terms and conditions:

(a)    EXERCISE PRICE.  The exercise price per Share under an Option shall be determined by the Committee; provided that the exercise price for any Option (other than an Option issued as a substitute Award pursuant to Section 14.14) shall not be less than the Fair Market Value as of the Grant Date.

(b)    PROHIBITION ON REPRICING.  Except as otherwise provided in Article 15, without the prior approval of shareholders of the Company: (i) the exercise price of an Option may not be reduced, directly or indirectly, (ii) an Option may not be cancelled in exchange for cash, other Awards, or Options or SARs with an exercise or base price that is less than the exercise price of the original Option or otherwise, and (iii) the Company may not repurchase an Option for value (in cash or otherwise) from a Participant if the current Fair Market Value of the Shares underlying the Option is lower than the exercise price per share of the Option.

(c)    TIME AND CONDITIONS OF EXERCISE.  The Committee shall determine the time or times at which an Option may be exercised in whole or in part, subject to Section 7.1(e).  The Committee shall also determine the performance or other conditions, if any, that must be satisfied before all or part of an Option may be exercised or vested.

9

(d)    PAYMENT.  The Committee shall determine the methods by which the exercise price of an Option may be paid, the form of payment and the methods by which Shares shall be delivered or deemed to be delivered to Participants.  As determined by the Committee at or after the Grant Date, payment of the exercise price of an Option may be made, in whole or in part, in the form of (i) cash or cash equivalents, (ii) delivery (by either actual delivery or attestation) of previously-acquired Shares based on the Fair Market Value of the Shares on the date the Option is exercised, (iii) withholding of Shares from the Option based on the Fair Market Value of the Shares on the date the Option is exercised, (iv) broker-assisted market sales, or (v) any other "cashless exercise" arrangement.

(e)    EXERCISE TERM.  No option granted under the Plan shall be exercisable for more than eight (8) years from the Grant Date.

(f)    NO DEFERRAL FEATURE.  No Option shall provide for any feature for the deferral of compensation other than the deferral of recognition of income until the exercise or disposition of the Option.

(g)    NO DIVIDEND EQUIVALENTS.  No Option shall provide for Dividend Equivalents.

(h)    SUSPENSION.  Any Participant who is also a participant in the Retirement at Micron ("RAM") Section 401(k) Plan and who requests and receives a hardship distribution from the RAM Plan, is prohibited from making, and must suspend, his or her employee elective contributions to the Plan.

7.2.    INCENTIVE STOCK OPTIONS.  The terms of any Incentive Stock Options granted under the Plan must comply with the requirements of Section 422 of the Code.  If all of the requirements of Section 422 of the Code are not met, the Option shall automatically become a Nonstatutory Stock Option.

ARTICLE 8
STOCK APPRECIATION RIGHTS 

8.1.    GRANT OF STOCK APPRECIATION RIGHTS.  The Committee is authorized to grant Stock Appreciation Rights to Participants on the following terms and conditions:

(a)    RIGHT TO PAYMENT.  Upon the exercise of a Stock Appreciation Right, the Participant to whom it is granted has the right to receive, for each Share with respect to which the Stock Appreciation Right is being exercised, the excess, if any, of:

(1)    The Fair Market Value of one Share on the date of exercise; over

(2)    The base price of the Stock Appreciation Right as determined by the Committee, which shall not be less than the Fair Market Value of one Share on the Grant Date.

(b)    PROHIBITION ON REPRICING.  Except as otherwise provided in Article 15, without the prior approval of shareholders of the Company: (i) the base price of a SAR may not be reduced, directly or indirectly, (ii) a SAR may not be cancelled in exchange for cash, other Awards, or Options or SARs with an exercise or base price that is less than the base price of the original SAR, and (iii) the Company may not repurchase a SAR for value (in cash or otherwise) from a Participant if the current Fair Market Value of the Shares underlying the SAR is lower than the base price per share of the SAR.

(c)    TIME AND CONDITIONS OF EXERCISE.  The Committee shall determine the time or times at which a SAR may be exercised in whole or in part.  No SAR granted under the Plan shall be exercisable for more than eight (8) years from the Grant Date.

10

(d)    NO DEFERRAL FEATURE.  No SAR shall provide for any feature for the deferral of compensation other than the deferral of recognition of income until the exercise or disposition of the SAR.

(e)    NO DIVIDEND EQUIVALENTS.  No SAR shall provide for Dividend Equivalents.

(f)    OTHER TERMS.  All awards of Stock Appreciation Rights shall be evidenced by an Award Certificate.  Subject to the limitations of this Article 8, the terms, methods of exercise, methods of settlement, form of consideration payable in settlement, and any other terms and conditions of any Stock Appreciation Right shall be determined by the Committee at the time of the grant of the Award and shall be reflected in the Award Certificate.

ARTICLE 9
PERFORMANCE SHARES

9.1.    GRANT OF PERFORMANCE SHARES.  The Committee is authorized to grant Performance Shares to Participants on such terms and conditions as may be selected by the Committee.  The Committee shall have the complete discretion to determine the number of Performance Shares granted to each Participant, subject to Section 5.4, and to designate the provisions of such Performance Shares as provided in Section 4.3.  All Performance Shares shall be evidenced by an Award Certificate or a written program established by the Committee, pursuant to which Performance Shares are awarded under the Plan under uniform terms, conditions and restrictions set forth in such written program.

9.2.    PERFORMANCE GOALS.  The Committee may establish performance goals for Performance Shares which may be based on any criteria selected by the Committee.  Such performance goals may be described in terms of Company-wide objectives or in terms of objectives that relate to the performance of the Participant, an Affiliate or a division, region, department or function within the Company or an Affiliate.  If the Committee determines that a change in the business, operations, corporate structure or capital structure of the Company or the manner in which the Company or an Affiliate conducts its business, or other events or circumstances render performance goals to be unsuitable, the Committee may modify such performance goals in whole or in part, as the Committee deems appropriate.  If a Participant is promoted, demoted or transferred to a different business unit or function during a performance period, the Committee may determine that the performance goals or performance period are no longer appropriate and may (i) adjust, change or eliminate the performance goals or the applicable performance period as it deems appropriate to make such goals and period comparable to the initial goals and period, or (ii) make a cash payment to the participant in amount determined by the Committee.  The foregoing two sentences shall not apply with respect to an Award of Performance Shares that is intended to be a Qualified Performance-Based Award if the recipient of such award (a) was a Covered Employee on the date of the modification, adjustment, change or elimination of the performance goals or performance period, or (b) in the reasonable judgment of the Committee, may be a Covered Employee on the date the Performance Award is expected to be paid.

9.3.    RIGHT TO PAYMENT.  The grant of a Performance Share to a Participant will entitle the Participant to receive at a specified later time a specified number of Shares, or the equivalent value in cash or other property, if the performance goals established by the Committee are achieved and the other terms and conditions thereof are satisfied.  The Committee shall set performance goals and other terms or conditions to payment of the Performance Shares in its discretion which, depending on the extent to which they are met, will determine the number of the Performance Shares that will be earned by the Participant.

9.4.    OTHER TERMS.  Performance Shares may be payable in cash, Stock, or other property, and have such other terms and conditions as determined by the Committee and reflected in the Award Certificate.

11

ARTICLE 10
RESTRICTED STOCK AND RESTRICTED STOCK UNIT AWARDS
    
10.1.    GRANT OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS.  Subject to the terms and conditions of this Article 10, the Committee is authorized to make Awards of Restricted Stock or Restricted Stock Units to Participants in such amounts and subject to such terms and conditions as may be selected by the Committee.  An Award of Restricted Stock or Restricted Stock Units shall be evidenced by an Award Certificate setting forth the terms, conditions, and restrictions applicable to the Award.

10.2.    ISSUANCE AND RESTRICTIONS.  Restricted Stock or Restricted Stock Units shall be subject to such restrictions on transferability and other restrictions as the Committee may impose (including, without limitation, limitations on the right to vote Restricted Stock or the right to receive dividends on the Restricted Stock).  Subject to the terms and conditions of the Plan, these restrictions may lapse separately or in combination at such times, under such circumstances, in such installments, upon the satisfaction of performance goals or otherwise, as the Committee determines at the time of the grant of the Award or thereafter.  Except as otherwise provided in an Award Certificate or any special Plan document governing an Award, the Participant shall have all of the rights of a stockholder with respect to the Restricted Stock, and the Participant shall have none of the rights of a stockholder with respect to Restricted Stock Units until such time as Shares of Stock are paid in settlement of the Restricted Stock Units.

10.3.    FORFEITURE.  Except as otherwise determined by the Committee at the time of the grant of the Award or thereafter, upon termination of Continuous Status as a Participant during the applicable restriction period or upon failure to satisfy a performance goal during the applicable restriction period, Restricted Stock or Restricted Stock Units that are at that time subject to restrictions shall be forfeited; provided, however, that the Committee may provide in any Award Certificate, subject to the terms and conditions of the Plan, that restrictions or forfeiture conditions relating to Restricted Stock or Restricted Stock Units will be waived in whole or in part in the event of terminations resulting from specified causes, including, but not limited to, death, Disability, or for the convenience or in the best interests of the Company.

10.4.    DELIVERY OF RESTRICTED STOCK.  Shares of Restricted Stock shall be delivered to the Participant at the time of grant either by book-entry registration or by delivering to the Participant, or a custodian or escrow agent (including, without limitation, the Company or one or more of its employees) designated by the Committee, a stock certificate or certificates registered in the name of the Participant.  If physical certificates representing shares of Restricted Stock are registered in the name of the Participant, such certificates must bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock.

10.5.    DIVIDENDS ON RESTRICTED STOCK.  In the case of Restricted Stock, the Committee may provide that ordinary cash dividends declared on the Shares before they are vested (i) will be forfeited, (ii) will be deemed to have been reinvested in additional Shares or otherwise reinvested (subject to Share availability under Section 5.1 hereof), or (iii) in the case of Restricted Stock that is not subject to performance-based vesting, will be paid or distributed to the Participant as accrued (in which case, such dividends must be paid or distributed no later than the 15th day of the 3rd month following the later of (A) the calendar year in which the corresponding dividends were paid to shareholders, or (B) the first calendar year in which the Participant's right to such dividends is no longer subject to a substantial risk of forfeiture).  Unless otherwise provided by the Committee, dividends accrued on Shares of Restricted Stock before they are vested shall, as provided in the Award Certificate, either (i) be reinvested in the form of additional Shares, which shall be subject to the same vesting provisions as provided for the host Award, or (ii) be credited by the Company to an account for the Participant and accumulated without interest until the date upon which the host Award becomes vested, and any dividends accrued with respect to forfeited Restricted Stock will be reconveyed to the Company without further consideration or any act or action by the Participant.  In no event shall dividends with respect to Restricted Stock that is subject to performance-based vesting be paid or distributed until the performance-based vesting restrictions of such Restricted Stock lapse.

12

ARTICLE 11
DEFERRED STOCK UNITS

11.1.    GRANT OF DEFERRED STOCK UNITS.  The Committee is authorized to grant Deferred Stock Units to Participants subject to such terms and conditions as may be selected by the Committee.  Deferred Stock Units shall entitle the Participant to receive Shares of Stock (or the equivalent value in cash or other property if so determined by the Committee) at a future time as determined by the Committee, or as determined by the Participant within guidelines established by the Committee in the case of voluntary deferral elections.  An Award of Deferred Stock Units shall be evidenced by an Award Certificate setting forth the terms and conditions applicable to the Award.

ARTICLE 12
DIVIDEND EQUIVALENTS

12.1.    GRANT OF DIVIDEND EQUIVALENTS.  The Committee is authorized to grant Dividend Equivalents with respect to Full-Value Awards granted hereunder to Participants subject to such terms and conditions as may be selected by the Committee.  Dividend Equivalents shall entitle the Participant to receive payments equal to ordinary cash dividends or distributions with respect to all or a portion of the number of Shares subject to a Full-Value Award, as determined by the Committee.  The Committee may provide that Dividend Equivalents (i) will  be deemed to have been reinvested in additional Shares or otherwise reinvested, or (ii) except in the case of Performance Shares, will be paid or distributed as accrued (in which case, such Dividend Equivalents must be paid or distributed no later than the 15 day of the 3rd month following the later of (i) the calendar year in which the corresponding dividends were paid to shareholders, or (ii) the first calendar year in which the Participant's right to such Dividends Equivalents is no longer subject to a substantial risk of forfeiture.  Unless otherwise provided by the Committee, Dividend Equivalents accruing on unvested Full-Value Awards shall, as provided in the Award Certificate, either (i) be reinvested in the form of additional Shares, which shall be subject to the same vesting provisions as provided for the host Award, or (ii) be credited by the Company to an account for the Participant and accumulated without interest until the date upon which the host Award becomes vested, and any Dividend Equivalents accrued with respect to forfeited Awards will be reconveyed to the Company without further consideration or any act or action by the Participant.  In no event shall Dividend Equivalents with respect to Performance Shares be paid or distributed until the performance-based vesting restrictions of the Performance Shares lapse.

ARTICLE 13
STOCK OR OTHER STOCK-BASED AWARDS

13.1.    GRANT OF STOCK OR OTHER STOCK-BASED AWARDS.  The Committee is authorized, subject to limitations under applicable law, to grant to Participants such other Awards that are payable in, valued in whole or in part by reference to, or otherwise based on or related to Shares, as deemed by the Committee to be consistent with the purposes of the Plan, including without limitation (but subject to Section 10.2) Shares awarded purely as a "bonus" and not subject to any restrictions or conditions, convertible or exchangeable debt securities, other rights convertible or exchangeable into Shares, and Awards valued by reference to book value of Shares or the value of securities of or the performance of specified Parents or Subsidiaries.  The Committee shall determine the terms and conditions of such Awards.

ARTICLE 14
PROVISIONS APPLICABLE TO AWARDS

14.1.    STAND-ALONE AND TANDEM AWARDS.  Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, any other Award granted under the Plan.  Subject to Section 16.2, awards granted in addition to or in tandem with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards.

13

14.2.    TERM OF AWARD.  The term of each Award shall be for the period as determined by the Committee, provided that in no event shall the term of any Incentive Stock Option or a Stock Appreciation Right granted in tandem with the Incentive Stock Option exceed a period of ten years from its Grant Date.

14.3.    FORM OF PAYMENT FOR AWARDS.  Subject to the terms of the Plan and any applicable law or Award Certificate, payments or transfers to be made by the Company or an Affiliate on the grant or exercise of an Award may be made in such form as the Committee determines at or after the Grant Date, including without limitation, cash, Stock, other Awards, or other property, or any combination, and may be made in a single payment or transfer, in installments, or (except with respect to Options or SARs) on a deferred basis, in each case determined in accordance with rules adopted by, and at the discretion of, the Committee.

14.4.    LIMITS ON TRANSFER.  No right or interest of a Participant in any unexercised or restricted Award may be pledged, encumbered, or hypothecated to or in favor of any party other than the Company or an Affiliate, or shall be subject to any lien, obligation, or liability of such Participant to any other party other than the Company or an Affiliate.  No unexercised or restricted Award shall be assignable or transferable by a Participant other than by will or the laws of descent and distribution or, except in the case of an Incentive Stock Option, pursuant to a domestic relations order that would satisfy Section 414(p)(1)(A) of the Code if such Section applied to an Award under the Plan; provided, however, that the Committee may (but need not) permit other transfers (other than transfers for value) where the Committee concludes that such transferability (i) does not result in accelerated taxation, (ii) does not cause any Option intended to be an Incentive Stock Option to fail to so qualify, and (iii) is otherwise appropriate and desirable, taking into account any factors deemed relevant, including without limitation, state or federal tax or securities laws applicable to transferable Awards.

14.5.    BENEFICIARIES.  Notwithstanding Section 14.4, a Participant may, in the manner determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to any Award upon the Participant's death.  A beneficiary, legal guardian, legal representative, or other person claiming any rights under the Plan is subject to all terms and conditions of the Plan and any Award Certificate applicable to the Participant, except to the extent the Plan and Award Certificate otherwise provide, and to any additional restrictions deemed necessary or appropriate by the Committee.  If no beneficiary has been designated or survives the Participant, any payment due to the Participant shall be made to the Participant's estate.  Subject to the foregoing, a beneficiary designation may be changed or revoked by a Participant, in the manner provided by the Company, at any time provided the change or revocation is filed with the Committee.

14.6.    STOCK TRADING RESTRICTIONS.  All Stock issuable under the Plan is subject to any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal or state securities laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted, or traded.  The Committee may place legends on any Stock certificate or issue instructions to the transfer agent to reference restrictions applicable to the Stock.

14.7.    ACCELERATION UPON A CHANGE IN CONTROL.  Except as otherwise provided in the Award Certificate or any special Plan document governing an Award, upon the occurrence of a Change in Control, all outstanding Options, SARs, and other Awards in the nature of rights that may be exercised shall become fully exercisable, and all time-based vesting restrictions on outstanding Awards shall lapse.  Except as otherwise provided in the Award Certificate or any special Plan document governing an Award, upon the occurrence of a Change in Control, the target payout opportunities attainable under all outstanding performance-based Awards shall be deemed to have been fully earned as of the effective date of the Change in Control based upon an assumed achievement of all relevant performance goals at the "target" level and there shall be prorata payout to Participants within thirty (30) days following the effective date of the Change in Control (or any later date required by Section 17.3 of the Plan) based upon the length of time within the performance period that has elapsed prior to the Change in Control.

    

14

14.8.    ACCELERATION UPON DEATH OR DISABILITY.  Except as otherwise provided in the Award Certificate or any special Plan document governing an Award, upon the Participant's death or Disability during his or her Continuous Status as a Participant, (i) all of such Participant's outstanding Options, SARs, and other Awards in the nature of rights that may be exercised shall become fully exercisable, (ii) all time-based vesting restrictions on the Participant's outstanding Awards shall lapse, and (iii) the target payout opportunities attainable under all of such Participant's outstanding performance-based Awards shall be deemed to have been fully earned as of the date of termination based upon an assumed achievement of all relevant performance goals at the "target" level and there shall be a prorata payout to the Participant or his or her estate within thirty (30) days following the date of termination (or any later date required by Section 17.3 of the Plan) based upon the length of time within the performance period that has elapsed prior to the date of termination.  Any Awards shall thereafter continue or lapse in accordance with the other provisions of the Plan and the Awards Certificate.  To the extent that this provision causes Incentive Stock Options to exceed the dollar limitation set forth in Code Section 422(d), the excess Options shall be deemed to be Nonstatutory Stock Options.

14.9.    ACCELERATION FOR ANY OTHER REASON.  Regardless of whether an event has occurred as described in Section 14.7 or 14.8 above, and subject to Section 5.5 as to Full-Value Awards and Section 14.11 as to Qualified Performance-Based Awards, the Committee may in its sole discretion at any time determine that all or a portion of a Participant's Options, SARs, and other Awards in the nature of rights that may be exercised shall become fully or partially exercisable, that all or a part of the time-based vesting restrictions on all or a portion of the outstanding Awards shall lapse, and/or that any performance-based criteria with respect to any Awards shall be deemed to be wholly or partially satisfied, in each case, as of such date as the Committee may, in its sole discretion, declare.  The Committee may discriminate among Participants and among Awards granted to a Participant in exercising its discretion pursuant to this Section 14.9.

14.10.    EFFECT OF ACCELERATION.  If an Award is accelerated under Section 14.7, Section 14.8 or Section 14.9, the Committee may, in its sole discretion, provide (i) that the Award will expire after a designated period of time after such acceleration to the extent not then exercised, (ii) that the Award will be settled in cash rather than Stock, (iii) that the Award will be assumed by another party to a transaction giving rise to the acceleration or otherwise be equitably converted or substituted in connection with such transaction, (iv) that the Award may be settled by payment in cash or cash equivalents equal to the excess of the Fair Market Value of the underlying Stock, as of a specified date associated with the transaction, over the exercise price of the Award, or (v) any combination of the foregoing.  The Committee's determination need not be uniform and may be different for different Participants whether or not such Participants are similarly situated.  To the extent that such acceleration causes Incentive Stock Options to exceed the dollar limitation set forth in Code Section 422(d), the excess Options shall be deemed to be Nonstatutory Stock Options.

14.11.    QUALIFIED PERFORMANCE-BASED AWARDS.

(a)    The provisions of the Plan are intended to ensure that all Options and Stock Appreciation Rights granted hereunder to any Covered Employee shall qualify for the Section 162(m) Exemption; provided that the exercise or base price of such Award is not less than the Fair Market Value of the Shares on the Grant Date.

(b)    When granting any other Award, the Committee may designate such Award as a Qualified Performance-Based Award, based upon a determination that the recipient is or may be a Covered Employee with respect to such Award, and the Committee wishes such Award to qualify for the Section 162(m) Exemption.  If an Award is so designated, the Committee shall establish performance goals for such Award within the time period prescribed by Section 162(m) of the Code based on one or more of the following Qualified Business Criteria, which may be expressed in terms of Company-wide objectives or in terms of objectives that relate to the performance of an Affiliate or a unit, division, region, department or function within the Company or an Affiliate:

15

		
	•
	Gross and/or net revenue (including whether in the aggregate or attributable to specific products)

		
	•
	Cost of Goods Sold and Gross Margin

		
	•
	Costs and expenses, including Research & Development and Selling, General & Administrative

		
	•
	Income (gross, operating, net, etc.)

		
	•
	Earnings, including before interest, taxes, depreciation and amortization (whether in the aggregate or on a per share basis

		
	•
	Cash flows and share price

		
	•
	Return on assets, investment, capital or equity

		
	•
	Manufacturing efficiency (including yield enhancement and cycle time reductions), quality improvements and customer satisfaction

		
	•
	Product life cycle management (including product and technology design, development, transfer, manufacturing introduction, and sales price optimization and management)

		
	•
	Economic profit or loss

		
	•
	Market share

		
	•
	Employee retention, compensation, training and development, including succession planning

		
	•
	Objective goals consistent with the Participant's specific duties and responsibilities, designed to further the financial, operational and other business interests of the Company, including goals and objectives with respect to regulatory compliance matters.

Performance goals with respect to the foregoing Qualified Business Criteria may be specified in absolute terms (including completion of pre-established projects, such as the introduction of specified products), in percentages, or in terms of growth from period to period or growth rates over time as well as measured relative to an established or specially-created performance index of Company competitors, peers or other members of high tech industries.  Any member of an index that disappears during a measurement period shall be disregarded for the entire measurement period.  Performance Goals need not be based upon an increase or positive result under a business criterion and could include, for example, the maintenance of the status quo or the limitation of economic losses (measured, in each case, by reference to a specific business criterion).

16

(c)    Each Qualified Performance-Based Award (other than an Option or SAR) shall be earned, vested and payable (as applicable) only upon the achievement of performance goals established by the Committee based upon one or more of the Qualified Business Criteria, together with the satisfaction of any other conditions, including the condition as to continued employment as set forth in subsection (g) below, as the Committee may determine to be appropriate; provided, however, that the Committee may provide, in its sole and absolute discretion, either in connection with the grant thereof or by amendment thereafter, that achievement of such performance goals will be waived upon the death or Disability of the Participant, or upon a Change in Control.  In addition, the Committee has the right, in connection with the grant of a Qualified Performance-Based Award, to exercise negative discretion to determine that the portion of such Award actually earned, vested and /or payable (as applicable) shall be less than the portion that would be earned, vested and/or payable based solely upon application of the applicable performance goals.  Performance periods established by the Committee for any such Qualified Performance-Based Award may be as short as ninety (90) days and may be any longer period.  In addition, the Committee has the right, in connection with the grant of a Qualified Performance-Based Award, to exercise negative discretion to determine that the portion of such Award actually earned, vested and/or payable (as applicable) shall be less than the portion that would be earned, vested and/or payable based solely upon application of the applicable performance goals.

(d)    The Committee may provide in any Qualified Performance-Based Award, at the time the performance goals are established, that any evaluation of performance shall include, exclude or otherwise equitably adjust for any  event that occurs during a performance period, including by way of example but without limitation the following: (a) asset write-downs or impairment charges; (b) litigation or claim judgments or settlements; (c) the effect of changes in tax laws, accounting principles or other laws or provisions affecting reported results; (d) accruals for reorganization and restructuring programs; (e) extraordinary nonrecurring items as described in then-current accounting principles and /or in management's discussion and analysis of financial condition and results of operations appearing in the Company's annual report to shareholders for the applicable year; (f) acquisitions or divestitures; and (g) foreign exchange gains and losses.  To the extent such inclusions or exclusions affect Awards to Covered Employees, they shall be prescribed in a form and at a time that meets the requirements of Code Section 162(m) for deductibility.

(e)    Any payment of a Qualified Performance-Based Award granted with performance goals pursuant to subsection (c) above shall be conditioned on the written certification of the Committee in each case that the performance goals and any other material conditions were satisfied.  Written certification may take the form of a Committee resolution passed by a majority of the Committee at a properly convened meeting or through unanimous action by the Committee via action by written consent.  The certification requirement also may be satisfied by a separate writing executed by the Chairman of the Committee, acting in his capacity as such, following the foregoing Committee action or by the Chairman executing approved minutes of the Committee in which such determinations were made.  Except as specifically provided in subsection (c), no Qualified Performance-Based Award held by a Covered Employee or an employee who in the reasonable judgment of the Committee may be a Covered Employee on the date of payment, may be amended, nor may the Committee exercise any discretionary authority it may otherwise have under the Plan with respect to a Qualified Performance-Based Award under the Plan, in any manner to waive the achievement of the applicable performance goal based on Qualified Business Criteria or to increase the amount payable pursuant thereto or the value thereof, or otherwise in a manner that would cause the Qualified Performance-Based Award to cease to qualify for the Section 162(m) Exemption.

(f)    Section 5.4 sets forth the maximum number of Shares that may be granted in any one-year period to a Participant in designated forms of stock-based Awards.

17

(g)    With respect to a Participant who is an officer of the Company, any payment of a Qualified Performance-Based Award granted with performance goals pursuant to subsection (c) above shall be conditioned on the officer having remained continuously employed by the Company or an Affiliate for the entire performance or measurement period, including, as well, through the date of determination and certification of the payment of any such Award pursuant to subsection (e) above (the "Certification Date").  For purposes of the Plan, with respect to any given performance or measurement period, an officer of the Company (i) who terminates employment (regardless of cause) or who otherwise ceases to be an officer, prior to the Certification Date, and (ii) who, pursuant to a separate contractual arrangement with the Company is entitled to receive payments from the Company thereunder extending to or beyond such Certification Date as a result of such termination or cessation in officer status, shall be deemed to have been employed by the Company as an officer through the Certification Date for purposes of payment eligibility.

14.12.    TERMINATION OF EMPLOYMENT.  Whether military, government or other service or other leave of absence shall constitute a termination of employment shall be determined in each case by the Committee at its discretion, and any determination by the Committee shall be final and conclusive.  A Participant's Continuous Status as a Participant shall not be deemed to terminate (i) in a circumstance in which a Participant transfers from the Company to an Affiliate, transfers from an Affiliate to the Company, or transfers from one Affiliate to another Affiliate, or (ii) in the discretion of the Committee as specified at or prior to such occurrence, in the case of a spin-off, sale or disposition of the Participant's employer from the Company or any Affiliate.  To the extent that this provision causes Incentive Stock Options to extend beyond three months from the date a Participant is deemed to be an employee of the Company, a Parent or Subsidiary for purposes of Sections 424(e) and 424(f) of the Code, the Options held by such Participant shall be deemed to be Nonstatutory Stock Options.

14.13.    FORFEITURE EVENTS.  Awards under the Plan shall be subject to any compensation recoupment policy that the Company will adopt from time to time, as required by law or otherwise, to the extent applicable.  In addition, the Committee may specify in an Award Certificate that the Participant's rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award.  Such events shall include, but shall not be limited to, termination of employment for cause, violation of material Company or Affiliate policies, breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Participant, or other conduct by the Participant that is detrimental to the business or reputation of the Company or any Affiliate, or a later determination that the vesting of, or amount realized from, a Performance Award was based on materially inaccurate financial statements or any other materially inaccurate performance metric criteria, whether or not the Participant caused or contributed to such material inaccuracy.

14.14.    SUBSTITUTE AWARDS.  The Committee may grant Awards under the Plan in substitution for stock and stock-based awards held by employees of another entity who become employees of the Company or an Affiliate as a result of a merger or consolidation of the former employing entity with the Company or an Affiliate or the acquisition by the Company or an Affiliate of property or stock of the former employing corporation.  The Committee may direct that the substitute awards be granted on such terms and conditions as the Committee considers appropriate in the circumstances.

18

ARTICLE 15
CHANGES IN CAPITAL STRUCTURE

15.1.    MANDATORY ADJUSTMENTS.  In the event of a nonreciprocal transaction between the Company and its shareholders that causes the per-share value of the Stock to change (including, without limitation, any stock dividend, stock split, spin-off, rights offering, or large nonrecurring cash dividend), the authorization limits under Section 5.1 and 5.4 shall be adjusted proportionately, and the Committee shall make such adjustments to the Plan and Awards as it deems necessary, in its sole discretion, to prevent dilution or enlargement of rights immediately resulting from such transaction.  Action by the Committee may include: (i) adjustment of the number and kind of shares that may be delivered under the Plan; (ii) adjustment of the number and kind of shares subject to outstanding Awards; (iii) adjustment of the exercise price of outstanding Awards or the measure to be used to determine the amount of the benefit payable on an Award; and (iv) any other adjustments that the Committee determines to be equitable.  Notwithstanding the foregoing, the Committee shall not make any adjustments to outstanding Options or SARs that would constitute a modification or substitution of the stock right under Treas. Reg. Sections 1.409A-1(b)(5)(v) that would be treated as the grant of a new stock right or change in the form of payment for purposes of Code Section 409A.  Without limiting the foregoing, in the event of a subdivision of the outstanding Stock (stock-split), a declaration of a dividend payable in Shares, or a combination or consolidation of the outstanding Stock into a lesser number of Shares, the authorization limits under Section 5.1 and 5.4 shall automatically be adjusted proportionately, and the Shares then subject to each Award shall automatically, without the necessity for any additional action by the Committee, be adjusted proportionately without any change in the aggregate purchase price therefore.

15.2.    DISCRETIONARY ADJUSTMENTS.  Upon the occurrence or in anticipation of any corporate event or transaction involving the Company (including, without limitation, any merger, reorganization, recapitalization, combination or exchange of shares, or any transaction described in Section 15.1), the Committee may, in its sole discretion, provide (i) that Awards will be settled in cash rather than Stock, (ii) that Awards will become immediately vested and non-forfeitable and exercisable (in whole or in part) and will expire after a designated period of time to the extent not then exercised, (iii) that Awards will be assumed by another party to a transaction or otherwise be equitably converted or substituted in connection with such transaction, (iv) that outstanding Awards may be settled by payment in cash or cash equivalents equal to the excess of the Fair Market Value of the underlying Stock, as of a specified date associated with the transaction (or the per-share transaction price), over the exercise or base price of the Award, (v) that performance targets and performance periods for Performance Shares will be modified, consistent with Code Section 162(m) where applicable, or (vi) any combination of the foregoing.  The Committee's determination need not be uniform and may be different for different Participants whether or not such Participants are similarly situated.

15.3.    GENERAL.  Any discretionary adjustments made pursuant to this Article 15 shall be subject to the provisions of Section 16.2.  To the extent that any adjustments made pursuant to this Article 15 cause Incentive Stock Options to cease to qualify as Incentive Stock Options, such Options shall be deemed to be Nonstatutory Stock Options.

19

ARTICLE 16
AMENDMENT, MODIFICATION AND TERMINATION

16.1.    AMENDMENT, MODIFICATION AND TERMINATION.  The Board or the Committee may, at any time and from time to time, amend, modify or terminate the Plan without stockholder approval; provided, however, that if an amendment to the Plan would, in the reasonable opinion of the Board or the Committee, either (i) materially increase the number of Shares available under the Plan, (ii) expand the types of awards under the Plan, (iii) materially expand the class of participants eligible to participate in the Plan, (iv) materially extend the term of the Plan, or (v) otherwise constitute a material change requiring stockholder approval under applicable laws, policies or regulations or the applicable listing or other requirements of an Exchange, then such amendment shall be subject to stockholder approval; and provided, further, that the Board or Committee may condition any other amendment or modification on the approval of shareholders of the Company for any reason, including by reason of such approval being necessary or deemed advisable to (i) to comply with the listing or other requirements of an Exchange, or (ii) to satisfy any other tax, securities or other applicable laws, policies or regulations.  Without the prior approval of the shareholders of the Company, the Plan may not be amended to permit: (i) the exercise price or base price of an Option or SAR to be reduced, directly or indirectly, (ii) an Option or SAR to be cancelled in exchange for cash, other Awards, or Options or SARs with an exercise or base price that is less than the exercise price or base price of the original Option or SAR, or otherwise, or (iii) the Company to repurchase an Option or SAR for value (in cash or otherwise) from a Participant if the current Fair Market Value of the Shares underlying the Option or SAR is lower than the exercise price or base price per share of the Option or SAR.

16.2.    AWARDS PREVIOUSLY GRANTED.  At any time and from time to time, the Committee may amend, modify or terminate any outstanding Award without approval of the Participant; provided, however:

(a)    Subject to the terms of the applicable Award Certificate, such amendment, modification or termination shall not, without the Participant's consent, reduce or diminish the value of such Award determined as if the Award had been exercised, vested, cashed in or otherwise settled on the date of such amendment or termination (with the per-share value of an Option or Stock Appreciation Right for this purpose being calculated as the excess, if any, of the Fair Market Value as of the date of such amendment or termination over the exercise or base price of such Award);

(b)    The original term of an Option or Stock Appreciation Right may not be extended without the prior approval of the shareholders of the Company;

(c)    Except as otherwise provided in Article 15, without the prior approval of the shareholders of the Company, (i) the exercise price of an Option or SAR may not be reduced, directly or indirectly, (ii) an option or SAR may not be cancelled in exchange for cash, other Awards or Options or SARs with an exercise or base price that is less than the exercise price or base price of the original Option or SAR, or otherwise, and (iii) the Company may not repurchase an Option or SAR for value (in cash or otherwise) from a Participant if the current Fair Market Value of the Shares underlying the Option or SAR is lower than the exercise price or base price per share of the Option or SAR; and

(d)    No termination, amendment, or modification of the Plan shall adversely affect any Award previously granted under the Plan, without the written consent of the Participant affected thereby.  An outstanding Award shall not be deemed to be "adversely affected" by a Plan amendment if such amendment would not reduce or diminish the value of such Award determined as if the Award had been exercised, vested, cashed in or otherwise settled on the date of such amendment (with the per-share value of an Option or Stock Appreciation Right for this purpose being calculated as the excess, if any, of the Fair Market Value as of the date of such amendment over the exercise or base price of such Award).

    

20

16.3.    COMPLIANCE AMENDMENTS.  Notwithstanding anything in the Plan or in any Award Certificate to the contrary, the Committee may amend the Plan or an Award Certificate, to take effect retroactively or otherwise, as deemed necessary or advisable for the purpose of conforming the Plan or Award Certificate to any present or future law relating to plans of this or similar nature (including, but not limited to, Section 409A of the Code), and to the administrative regulations and rulings promulgated thereunder.  By accepting an Award under this Plan, a Participant agrees to any amendment made pursuant to this Section 16.3 to any Award granted under the Plan without further consideration or action.

ARTICLE 17
GENERAL PROVISIONS

17.1.    NO RIGHTS TO AWARDS; NON-UNIFORM DETERMINATIONS.  No Participant or any Eligible Participant shall have any claim to be granted any Award under the Plan.  Neither the Company, its Affiliates nor the Committee is obligated to treat Participants or Eligible Participants uniformly, and determinations made under the Plan may be made by the Committee selectively among Eligible Participants who receive, or are eligible to receive, Awards (whether or not such Eligible Participants are similarly situated).

17.2.    NO STOCKHOLDER RIGHTS.  No Award gives a Participant any of the rights of a stockholder of the Company unless and until Shares are in fact issued to such person in connection with such Award.

17.3.    SPECIAL PROVISIONS RELATED TO SECTION 409A OF THE CODE.

(a)    It is intended that the payments and benefits provided under the Plan and any Award shall either be exempt from the application of, or comply with, the requirements of Section 409A of the Code.  The Plan and all Award Certificates shall be construed in a manner that effects such intent.  Nevertheless, the tax treatment of the benefits provided under the Plan or any Award is not warranted or guaranteed.  Neither the Company, its Affiliates nor their respective directors, officers, employees or advisers (other than in his or her capacity as a Participant) shall be held liable for any taxes, interest, penalties or other monetary amounts owed by any Participant or other taxpayer as a result of the Plan or any Award.

(b)    Notwithstanding anything in the Plan or in any Award Certificate to the contrary, to the extent that any amount or benefit that would constitute non-exempt "deferred compensation" for purposes of Section 409A of the Code ("Non-Exempt Deferred Compensation") would otherwise be payable or distributable, or a different form of payment (e.g., lump sum or installment) would be effected, under the Plan or any Award Certificate by reason of the occurrence of a Change in Control, or the Participant's Disability or separation from service, such Non-Exempt Deferred Compensation will not be payable or distributable to the Participant, and/or such different form of payment will not be effected, by reason of such circumstance unless the circumstances giving rise to such Change in Control, Disability or separation from service meet any description or definition of "change in control event", "disability" or "separation from service", as the case may be, in Section 409A of the Code and applicable regulations (without giving effect to any elective provisions that may be available under such definition).  This provision does not prohibit the vesting of any Award upon a Change in Control, Disability or separation from service, however defined.  If this provision prevents the payment or distribution of any amount or benefit, or the application of a different form of payment of any amount or benefit, such payment or distribution shall be made at the time and in the form that would have applied absent the Change in Control, Disability or separation from service, as applicable.

(c)    If any one or more Awards granted under the Plan to a Participant could qualify for any separation pay exemption described in Treas. Reg. Section 1.409A-1(b)(9), but such Awards in the aggregate exceed the dollar limit permitted for the separation pay exemptions, the Company (acting through the Committee or the Company's Chief Executive Officer) shall determine which Awards or portions thereof will be subject to such exemptions.

21

(d)    Notwithstanding anything in the Plan or in any Award Certificate to the contrary, if any amount or benefit that would constitute Non-Exempt Deferred Compensation would otherwise be payable or distributable under this Plan or any Award Certificate by reason of a Participant's separation from service during a period in which the Participant is a Specified Employee (as defined below), then, subject to any permissible acceleration of payment by the Committee under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes):

(i)    if the payment or distribution is payable in a lump sum, the Participant's right to receive payment or distribution of such Non-Exempt Deferred Compensation will be delayed until the earlier of the Participant's death or the first day of the seventh month following the Participant's separation from service; and

(ii)    if the payment or distribution is payable over time, the amount of such Non-Exempt Deferred Compensation that would otherwise be payable during the six-month period immediately following the Participant's separation from service will be accumulated and the Participant's right to receive payment or distribution of such accumulated amount will be delayed until the earlier of the Participant's death or the first day of the seventh month following the Participant's separation from service, whereupon the accumulated amount will be paid or distributed to the Participant and the normal payment or distribution schedule for any remaining payments or distributions will resume.

For purposes of this Plan, the term "Specified Employee" has the meaning given such term in Code Section 409A and the final regulations thereunder, provided, however, that, as permitted in such final regulations, the Company's Specified Employees and its application of the six-month delay rule of Code Section 409A(a)(2)(B)(i) shall be determined in accordance with rules adopted by the Board or any committee of the Board, which shall be applied consistently with respect to all nonqualified deferred compensation arrangements of the Company, including this Plan.

(e)    If, pursuant to an Award, a Participant is entitled to a series of installment payments, such Participant's right to the series of installment payments shall be treated as a right to a series of separate payments and not to a single payment.  For purposes of the preceding sentence, the term "series of installment payments" has the meaning provided in Treas. Reg. Section 1.409A-2(b)(2)(iii) (or any successor thereto).

(f)    The Company shall have the sole authority to make any accelerated distribution permissible under Treas. Reg. section 1.409A-3(j)(4) to Participants of deferred amounts, provided that such distribution(s) meets the requirements of Treas. Reg. section 1.409A-3(j)(4).

(g)    Whenever an Award conditions a payment or benefit on the Participant's execution and non-revocation of a release of claims, such release must be executed and all revocation periods shall have expired within 60 days after the date of termination of the Participant's employment; failing which such payment or benefit shall be forfeited.  If such payment or benefit is exempt from Section 409A of the Code, the Company may elect to make or commence payment at any time during such 60-day period.  If such payment or benefit constitutes Non-Exempt Deferred Compensation, then, subject to subsection (d) above, (i) if such 60-day period begins and ends in a single calendar year, the Company may make or commence payment at any time during such period at its discretion, and (ii) if such 60-day period begins in one calendar year and ends in the next calendar year, the payment shall be made or commence during the second such calendar year (or any later date specified for such payment under the applicable Award), even if such signing and non-revocation of the release occur during the first such calendar year included within such 60-day period.

22

17.4.    WITHHOLDING.  The Company or any Affiliate shall have the authority and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, and local taxes (including the Participant's FICA obligation) required by law to be withheld with respect to any exercise, lapse of restriction or other taxable event arising as a result of the Plan.  With respect to withholding required upon any taxable event under the Plan, the Committee may, at the time the Award is granted or thereafter, require or permit that any such withholding requirement be satisfied, in whole or in part, by withholding from the Award Shares having a Fair Market Value on the date of withholding equal to the minimum amount (and not any greater amount) required to be withheld for tax purposes, all in accordance with such procedures as the Committee establishes.  All such elections shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

17.5.    NO RIGHT TO CONTINUED SERVICE.  Nothing in the Plan, any Award Certificate or any other document or statement made with respect to the Plan, shall interfere with or limit in any way the right of the Company or any Affiliate to terminate any Participant's employment or status as an officer, director or consultant at any time, nor confer upon any Participant any right to continue as an employee, officer, director or consultant of the Company or any Affiliate, whether for the duration of a Participant's Award or otherwise.  Neither an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company or any Affiliate and, accordingly, subject to Article 16, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Board of Directors without giving rise to any liability on the part of the Company or an of its Affiliates.

17.6.    UNFUNDED STATUS OF AWARDS.  The Plan is intended to be an "unfunded" plan for incentive and deferred compensation.  With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Certificate shall give the Participant any rights that are greater than those of a general creditor of the Company or any Affiliate.  This Plan is not intended to be subject to ERISA.

17.7.    RELATIONSHIP TO OTHER BENEFITS.  No payment under the Plan shall be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or benefit plan of the Company or any Affiliate unless provided otherwise in such other plan.

17.8.    EXPENSES.  The expenses of administering the Plan shall be borne by the Company and its Affiliates.

17.9.    TITLES AND HEADINGS.  The titles and headings of the Sections in the Plan are for convenience of reference only, and in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.

17.10.    GENDER AND NUMBER.  Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine; the plural shall include the singular and the singular shall include the plural.

17.11.    FRACTIONAL SHARES.  No fractional Shares shall be issued and the Committee shall determine, in its discretion, whether cash shall be given in lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding up or down.

    

23

17.12.    GOVERNMENT AND OTHER REGULATIONS.

(a)    Notwithstanding any other provision of the Plan, no Participant who acquires Shares pursuant to the Plan may, during any period of time that such Participant is an affiliate of the Company (within the meaning of the rules and regulations of the Securities and Exchange Commission under the 1933 Act), sell such Shares, unless such offer and sale is made (i) pursuant to an effective registration statement under the 1933 Act, which is current and includes the Shares to be sold, or (ii) pursuant to an appropriate exemption from the registration requirement of the 1933 Act, such as that set forth in Rule 144 promulgated under the 1933 Act.

(b)    Notwithstanding any other provision of the Plan, if at any time the Committee shall determine that the registration, listing or qualification of the Shares covered by an Award upon any Exchange or under any foreign, federal, state or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the granting of such Award or the purchase or receipt of Shares thereunder, no Shares may be purchased, delivered or received pursuant to such Award unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any condition not acceptable to the Committee.  Any Participant receiving or purchasing Shares pursuant to an Award shall make such representations and agreements and furnish such information as the Committee may request to assure compliance with the foregoing or any other applicable legal requirements.  The Company shall not be required to issue or deliver any certificate or certificates for Shares under the Plan prior to the Committee's determination that all related requirements have been fulfilled.  The Company shall in no event be obligated to register any securities pursuant to the 1933 Act or applicable state or foreign law or to take any other action in order to cause the issuance and delivery of such certificates to comply with any such law, regulation or requirement.

17.13.    GOVERNING LAW.  To the extent not governed by federal law, the Plan and all Award Certificates shall be construed in accordance with and governed by the laws of the State of Delaware.

17.14.    ADDITIONAL PROVISIONS.  Each Award Certificate may contain such other terms and conditions as the Committee may determine; provided that such other terms and conditions are not inconsistent with the provisions of the Plan.

17.15.    NO LIMITATIONS ON RIGHTS OF COMPANY.  The grant of any Award shall not in any way affect the right or power of the Company to make adjustments, reclassification or changes in its capital or business structure or to merge, consolidate, dissolve, liquidate, sell or transfer all or any part of its business or assets.  The Plan shall not restrict the authority of the Company, for proper corporate purposes, to draft or assume awards, other than under the Plan, to or with respect to any person.  If the Committee so directs, the Company may issue or transfer Shares to an Affiliate, for such lawful consideration as the Committee may specify, upon the condition or understanding that the Affiliate will transfer such Shares to a Participant in accordance with the terms of an Award granted to such Participant and specified by the Committee pursuant to the provisions of the Plan.

24

17.16.    INDEMNIFICATION.  Each person who is or shall have been a member of the Committee, or of the Board, or an officer of the Company to whom authority was delegated in accordance with Article 4 shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company's approval, or paid by him or her in satisfaction of any judgment in any such action, suit, or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf, unless such loss, cost, liability, or expense is a result of his or her own willful misconduct or except as expressly provided by statute.  The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company's Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.

17.17.    SEVERABILITY.  In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any applicable law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein.

25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]